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ABSTRACT
In photodynamic therapy a photosensitizer drug is administered and is irradiated with light. Upon
absorption of light the photosensitizer goes into its triplet state and transfers energy or an
electron to oxygen to form reactive oxygen species (ROS). These ROS react with biomolecules
in cells leading to cell damage and cell death. PDT has interested many researchers because of its
non-invasiveness as compared to surgery, it leaves little to no scars, it is time and costs effective,
it has potential for targeted treatment, and can be repeated as needed. A number of
photosensitizers have been approved by the FDA for clinical application of PDT. PDT is
currently used in early-stage cancers of the head and neck, in treating advanced cancer by
shrinking the tumor, basal cell skin cancer, and Bowen’s disease among others. Research is
currently in progress to improve the optical properties and clinical applicability of
photosensitizers.
Different photosensitizers such as porphyrines, chlorophylls, and dyes have been used in PDT to
treat various cancers, skin diseases such as acne vulgaris, aging and sun-damaged skin.
Historically, these have been divided into first and second generation sensitizers. Low extinction
coefficients, presence of impurities, and skin phototoxicity were characteristic for first
generation sensitizers. With the second generation of sensitizers, which include Porphyrins,
Chlorophylls, Bacteriopheophorbides, Texaphyrins, Phtalocyanines, and dyes such as
Anthraquinones, Rose Bengal, and Methylene Blue, attempts were made to improve upon these
issues. Skin sensitivity was reduced and extinction coefficients were brought up to ~ 105 L mol-1
cm-1. The porphyrine family is comprised of photosensitizers such as HpD (hematoporphyrin
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derivative), BPD (benzoporphyrin derivative), ALA (5-aminolevulinic acid), Vertiporfin, and
Texaphyrins. The Chlorophylls group of photosensitizers, prepared from base of purple bacteria
and blue-green algae, includes Chlorins, Purpurins and Bacteriochlorins and show deep red
absorption. Dyes such as Phtalocyanine, Napthalocyanine, Rose Bengal, and Methylene Blue are
often used as photosensitizers as well. While PDT based on these small molecule
photosensitizers has shown great promise, only a handful (mainly Photofrin, ALA, Vertiporfin,
and Phthalocyanine) have been clinically approved. The main issues with current sensitizers are
(i) hydrophobicity leading to aggregation in aqueous media resulting in reduced efficacy and
potential toxicity, (ii) dark toxicity of photosensitizers, (iii) non-selectivity towards malignant
tissue resulting in prolonged cutaneous photosensitivity and damage to healthy tissue, (iv)
limited light absorption efficiency, and (v) a lack of understanding of where the photosensitizer
ends up in the tissue.
In this dissertation research program, these issues were addressed by the development of
conducting polymer nanoparticles as a next generation of photosensitizers. This choice was
motivated by the fact that conducting polymers have large extinction coefficients (> 107 L mol-1
cm-1), are able to undergo intersystem crossing to the triplet state, and have triplet energies that
are close to that of oxygen. It was therefore hypothesized that such polymers could be effective
at generating ROS due to the large excitation rate that can be generated. The hydrophobicity of
these polymers was hypothesized to be able to contribute to the fabrication of conducting
polymer nanoparticles that are dispersible and stable in aqueous media. The resulting organic
nanoparticles were expected to exhibit reasonable biocompatibility (in dark) due to the absence
of impurities, heavy metals, or redox active moieties. Targeting of these conducting polymer
iii

nanoparticles was hypothesized to be feasible based on the development of blended nanoparticles
containing amphiphilic polymers with chemically active moieties. Finally, these conducting
polymers are brightly fluorescent, which lead to the hypothesis that this property may allow for
facile in-vitro localization and tracking.
First, conducting polymer nanoparticles (CPNPs) composed of the conducting polymer poly[2methoxy-5-(2-ethylhexyl-oxy)-p-phenylenevinylene] (MEH-PPV) and 50 wt% Phenyl-C61butyric acid methyl ester (PCBM) were fabricated and characterized together with the
corresponding undoped (pure MEH-PPV) nanoparticles. The addition of PCBM was
hypothesized to result in greater efficiency of ROS generation by ultrafast charge transfer from
MEH-PPV to PCBM. The nanoparticles were fabricated by reprecipitation method, in which
MEH-PPV polymer or mixed MEH-PPV/PCBM solution in THF (tetrahydrofuran) is injected in
water. THF was selected as solvent due to its miscibility with water and good solubility of MEHPPV and PCBM in THF. Due to its hydrophobic properties the polymer aggregates with itself
when exposed to water to self-assemble into nanoparticles. These nanoparticles remain
suspended in water and are well dispersed. The nanoparticles were found to be stable in buffer
and culture media. Both types of nanoparticles were found to exhibit no cytotoxicity in dark,
however, human breast cancer cell lines did exhibit dark toxicity at the highest NP dose used
herein for the MEH-PPV/PCBM nanoparticles. Due to this observation, together with quenched
fluorescence emission of MEH-PPV due to the presence of PCBM, and the limited potential of
clinical application of fullerenes these blended nanoparticles were not considered further after
initial study. Selectivity of nanoparticle uptake was studied by fluorescence microscopy and flow
cytometry. Although not fully selective, the nanoparticles exhibited a strong bias to the cancer
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cells, which is attributed to the hydrophobicity of the nanoparticles and aggressiveness of cancer
cells with respect to normal cells. For the cancer cell lines studied, uptake increased from MDAMB-231 followed by A549 to OVCAR3. The formation of ROS was proven in-vitro by staining
of the cells with CellROX Green Reagent, after which PDT results were quantified by MTT
assays. Cell mortality was observed to scale with nanoparticle dosage and light dosage. Cell
death was observed for the complete OVCAR3 population treated by NPs, and mainly proceed
by apoptosis. In general, the fullerene doped NPs were found to be almost 30 % more effective
than the undoped CPNPs, but these NPs were not considered further after these studies for
reasons given above.
Second, the MEH-PPV nanoparticles were developed further to allow for surface
functionalization, with the aim of targeting these NPs to specific cancer cell lines as determined
by the ligand that is conjugated. This task was accomplished by blending MEH-PPV with
Polystyrene Graft Ethylene Oxide with carboxylic acid (PS-PEG-COOH) into nanoparticles. It
was hypothesized that the hydrophobic block of the PS-PEG-COOH polymer would integrate
with the nanoparticle core, while the hydrophilic block would remain on the surface and extend
into the aqueous media. Folic acid was successfully conjugated to MEH-PPV/PS-PEG-COOH
nanoparticles (MPNPs) as the targeting ligand by EDC chemistry with the aim to selectively
target cancer cells that overexpress folate receptors (FR). These functionalized nanoparticles
(FNPs) were studied in OVCAR3 (ovarian cancer cell line) as FR+, MIA PaCa2 (pancreatic
cancer cell line) as FR-, and A549 (lung cancer cell line) having marginal FR expression.
Complete selectivity of the FNPs towards the FR+ cell line was found, and is attributed to the
hydrophobicity and large negative zeta potential of the nanoparticles, which reduces the
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statistical probability of non-specific uptake to virtually zero. The abundant uptake of the FNPs
by the FR+ cell line (OVCAR3) compared to the marginal uptake of FNPs by the cell line with
marginal FR expression (A549) further confirms the selectivity of the FNPs due to the
aforementioned properties as well as being due to the receptor mediated uptake mechanism.
Quantification of PDT results by MTS assays and flow cytometry show that PDT treatment was
fully selective to the FR+ cell line (OVCAR3). No cell mortality was observed for the other cell
lines studied here within experimental error.
Finally, the issue of confirming and quantifying small molecule drug delivery to diseased tissue
was

tackled

by

developing

quantum

dot

(Qdot)

biosensors.

Initially,

a

multifunctional/multimodal composite activatable nanoprobe (MMCNP) was developed, with
the aim to enable magnetic resonance imaging (MRI) for MMCNP tracking and fluorescence
reporting of intracellular small molecule/drug delivery. It was hypothesized that MRI activity
could be achieved with the integration of paramagnetic ironoxide core nanoparticles, while
fluorescence reporting could be achieved by attaching functionalized Qdots to the ironoxide core
nanoparticle. For fluorescence reporting prior expertise in control of the fluorescence state of
Qdots was employed, where redox active ligands can place the Qdot in a quenched OFF state.
Ligand attachment, including folic acid for targeting and STAT3 anticancer drug, was
accomplished by disulfide linker chemistry, which was hypothesized to be reversible in the
presence of sulfur reducing biomolecules, resulting in Qdots in a brightly fluorescent ON state.
Glutathione (GSH) is such a biomolecule that is present in the intracellular environment.
Experimental data shows that this design was successfully implemented. Fluorescence
restoration of Qdots was observed in the intracellular environment of cancer cells confirming
vi

delivery of ligands including STAT3 anticancer drug, the MMCNPs showed targeted uptake by
cancer cell lines, MRI activity was proven in a phantom, and cancer cell viability was reduced by
30% with respect to the control. In addition, the MMCNP facilitated targeted delivery of the
STAT3 anticancer drug, so that a 15% improvement in treatment efficiency was observed
compared to treatment with free drug.
An updated biosensor probe was recently developed to both confirm delivery of small
molecule/drug to intracellular and quantify the amount of drug delivered. For fluorescence
reporting of the delivery event prior expertise in control of the fluorescence state of Qdots was
employed again, where the redox active dopamine ligands placed the Qdot surface as quenchers
OFF state). Since the Qdot fluorescence restoration was found to be dependent on the amount of
ligands removed from the Qdot surface, the probe was designed to allow for ratiometric
quantification. A folic acid (targeting) and dye (ratiometric standard) labeled chitosan shell was
fabricated on the dopamine/cargo functionalized Qdot surface. It was hypothesized that a
ratiometric measurement of the fluorescence of Qdot (changing with the amount of cargo
released) with respect to the constant emission of a dye in the chitosan shell could provide a
quantitative measurement of the cargo released in the cells. Current experimental work shows
that the quenching of Qdot fluorescence occurs through an electron transfer process from or to
the Qdots depending on conjugation of the oxidized (quinone) form of dopamine or reduced
(catechol) form of the dopamine, respectively, as revealed from single particle spectroscopy data.
Epiluminescence imaging to determine uptake of the probe showed limited internalization of the
probe by the cell lines due to aggregation of the probe in the aqueous media, together with the
absence of dopamine receptors on the membranes of cell lines studied herein (A549 and
vii

OVCAR3). However, Restoration of Qdot fluorescence due to displacement of dopamine with
intracellular GSH was observed in the cells. Though the uptake of the probe was limited, the
intracellular single particle spectroscopy data collected on cells that have internalized the probe,
give a promising proof of concept.
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CHAPTER 1

1.1

SIGNIFICANCE AND BACKGROUND

Background
1.1.1

Statistical surveys on cancer

The American Society of Clinical Oncology (ASCO) has come up with a cancer progress
timeline since the first chemotherapy in 1949 including the new targeted treatments for nearly
120 types of cancers [1]. As shown in Figure 1.1A, the nation’s cancer death has reduced by 18%
since 1990 after the continuous increase. This is due to the advances in every area of cancer
treatment such as prevention, screening, chemotherapy, radiotherapy, surgery, and recently the
targeted treatments. Also the improved managements in side effects after the treatment enabled
patients to live better lives. The percent of patients surviving at least for 5 years after the
diagnosis of cancer has also increased gradually throughout these years (Figure 1.1B), though the
number of cases of cancer is still increasing (Figure 1.1C). More recent statistics on survival of
cancer adapted from the American Cancer Society's publication, Cancer Facts & Figures 2014,
and the National Cancer Institute Office of Cancer Survivorship showed that the number of
people with a history of cancer in the United States has increased dramatically, from 3 million in
1971 to about 13.7 million today. Of these, an estimated 379,112 are survivors of childhood and
adolescent cancer, which means they were diagnosed before the age of 20. About 68% of today’s
cancer survivors were diagnosed with cancer five or more years ago. And, approximately 15% of
all cancer survivors were diagnosed 20 or more years ago. More than half of cancer survivors are
65 or older. An estimated 1 in 530 adults between the ages of 20 and 39 is a survivor of
childhood cancer.
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Figure 1.1 A) mortality of cancer patients through 1970-2010 showing decrease in death of
cancer patients, B) percent of patients surviving for five years increase through 1970-2010, C)
new cases of cancer still increasing.

The increase in survival percent throughout these years can be attributed to improved diagnostic
methods, improvements in treatments, better management of side effects and new targeted
2

therapies. The SEER stat fact sheets released by National Cancer Institute show that even if the
pancreatic cancer is only 2.8% (number of patients - 46, 420) of all new cancer cases in 2014, the
estimated survival of patients with pancreatic cancer is only 6.7 [2]. They have found that liver
cancer is only 2 % of all the new cancer cases (number of patients – 33,190), while the estimated
survival rate is 16.6 %. The lung cancer is 13.5 % of all new cases and the survival is as low as
the liver cancer. Thus even if fight against cancer is improving throughout these years, there are
still some types of cancers that need more research to have a safer and effective treatment.

1.1.2

Available treatments for cancer

Various treatments of cancer include surgery [3, 4], radiotherapy [5, 6], and chemotherapy [711]. Surgery can be done by different methods. Most of the surgeries follow radiotherapy or
chemotherapy to remove the remaining cancer cells after surgery. Some common types of
surgery are 1) cryosurgery in which cold material such as liquid nitrogen spray or cold probe is
used to freeze the cells and destroy them.[12], 2) electrosurgery in which high-frequency electric
currents are given, 3) laser surgery in which high intensity light is used to shrink or vaporize the
cancer cells, 4) Mohs surgery in which cancer cells at sensitive areas such as eye, skin are
removed layer by layer until all the cancerous tissue has been removed, 5) laparoscopic surgery
in which laparoscope is used to see inside the body. Many small incisions are made and a tiny
camera is inserted in the body, 6) natural orifice surgery in which surgical tools are passed
through a natural body opening such as mouth, rectum or vagina, 7) robotic surgery in which the
surgeon uses hand controls that tell a robot how to use surgical tools for operation. This helps the
surgeon to operate areas which are hard to reach. Developments have been made in surgery
techniques by using lasers [13-17] and fluorescence imaging guided surgery [18, 19]. In laser
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surgery 63 patients with tracheobronchial tumors were treated with lasers to burn the tumor
tissue. The results were very impressive as shown in Table 1.1 [20]
Table 1.1 Results for surgery using laser beam [20]

In fluorescence imaging guided surgery 139 out of 270 patients were randomly assigned with 20
mg/kg bodyweight 5-aminolevulinic acid (5-ALA) which is non-fluorescent prodrug that leads to
intracellular accumulation of fluorescent porphyrins in malignant glioma. After resection on the
139 patients (assigned to 5 ALA) and the remaining 131 patients (assigned to white light) a
survey was done after 6 months for progression-free survival. They observed that the tumor was
completely resected in 90 patients (65%) of 139 who were assigned with 5-ALA, while only 47
patients (36%) of 131 assigned with white light had the tumor completely resected [18]. The total
results are shown in Figure 1.2.
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Figure 1.2 Progression-free survival after resection in 5-ALA assigned (red line) and white light
assigned (black light) patients.[18]

An example of intraoperative near infrared fluorescence imaging surgery is to give breast cancer
patients

99m

Tc-sulfur colloid lymphoscintigraphy followed by 12.5 µg of indocyanine green

(ICG) diluted in human serum albumin (HSA) as NIR fluorescent lymphatic tracer.

Figure 1.3 Breast Cancer Sentinel Lymph Nodes Mapping and resection using NIR fluorescence
imaging guided surgery.[19]
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Breast Cancer Sentinel Lymph Nodes were identified and resected in 9 breast cancer patients
(Figure 1.3) [19].

1.1.3 Recent developments of small molecule and nanoparticle anticancer drugs
A lot of research has been done and is still in progress on developing drugs for effective
treatment of cancer. The most common drugs to date to be used in cancer therapy are
doxorubicin, paclitaxel and STAT3 inhibitors.

1.1.3.1 Small molecule drugs

Doxorubicin, like other anthracycline molecules intercalates with DNA and partially uncoil the
double-stranded helix [21, 22]. Doxorubicin has high affinity for cell nuclei and as much as 60%
of the total intracellular amount of doxorubicin is found in the nucleus. Once it is bound to DNA,
it inhibits DNA polymerase and nucleic acid synthesis and also disrupts the topoisomerase-IImediated DNA repair, resulting in the formation of protein-linked DNA double strand breaks. In
tumor cells, the anthracycline-induced perturbations result in a pathway of endonucleolytic DNA
fragmentation known as apoptosis. Because proliferation is important of tumor growth,
interference with the genome is the primary cause of the anti-tumor action of doxorubicin.
Doxorubicin acts as anti-tumor drug in one other way also. It is assumed to form free radicals in
the subcellular environment. In short, doxorubicin gets oxidized to semiquinone, an unstable
metabolite, presumably by NADH dehyrogenases, nitric oxide synthases or xanthine oxidases,
and is converted back to doxorubicin in a process that releases reactive oxygen species. The
reactive oxygen species then lead to lipid peroxidation and membrane damage, DNA damage,
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oxidative stress, and triggers apoptosis [22]. Doxorubicin has been used to treat a variety of types
of cancer [23]. It has been used to treat cervical cancer [24], endometrical cancer [25], pancreatic
cancer [26, 27], prostate cancer [28], head and neck cancer [29], skin cancer [28], bone cancer
[30], lung cancer [31], breast cancer [32], stomach cancer [33], soft tissue sarcoma [28] etc..
The second most commonly used drug is the STAT3 inhibitors. It works by inhibiting the
STAT3, the signal transducer and activator of transcription [34-37]. STAT3 is a transcription
factor which plays a key role in normal cell growth [37] and is highly activated in about 70%
cancers [35, 37].

Figure 1.4 Strategies of STAT inhibition in tumor cells.[37]

The activated STAT3 is phosphorylated forming a dimer which enters the nucleus via interaction
with importins and binds target genes. Inhibition of STAT3 results in the death of tumor cells
(Figure 1.4). STAT3 inhibitor drug has been shown to have effective results in treating various
cancer cell lines [38]. The breast carcinoma cell lines (MDA-MB-231 and MDA-MB-435),
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pancreatic cancer cells (Panc-1) and NIH3T3/v-Src fibroblasts showed inhibition in the growth
when incubated with STAT3 [39]. Prostate cancer cells in-vivo showed growth inhibition and
increased apoptosis (Figure 1.5) [40]. Though this path to fight cancer seems very easy, there are
only a small number of STAT3 direct inhibitors. Also, the STAT1 (another STAT family
member) which helps in apoptosis, cell death and defense against pathogens is very similar with
STAT3. This similarity requires that STAT3-inhibitors have no effect on STAT1 [34, 36].

Figure 1.5 Apoptosis induced by STAT3 in prostate cancer cells.

Paclitaxel also called as taxol is an antitumor drug which affects the microtubule formation
during mitosis and inhibit the growth of cancer cells [41]. Microtubules are also critical for the
performance of many important cell functions, such as maintenance of cell shape, cellular
motility and attachment, and intracellular transport. Microtubules are always in a dynamic
equilibrium with their basic protein subunits, tubulin dimers. Taxol promotes microtubule
assembly and stabilizes microtubules by shifting the dynamic equilibrium toward microtubule
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assembly [42-45]. Taxol concentrations as low as 0.05 µmol/L shift the equilibrium in favor of
microtubule formation by decreasing the lag time for microtubule assembly [45]. This way taxol
decreases the critical concentration of tubulin required for microtubule assembly during mitosis
[46, 47]. Microtubules treated with taxol are stable even after treatment with calcium or low
temperatures, conditions that usually promote disassembly [44, 45, 48]. This unusual stability
results in inhibition of the normal dynamic reorganization of the microtubule network inhibiting
the growth of cancer cells [49].

1.1.3.2

Nanoparticles for drug delivery

Most of the drugs are hydrophobic posing a problem of delivery in blood circulation. This
reduces the efficacy of the therapeutic drug. Research has been done to deliver the hydrophobic
drugs more efficiently by encapsulating or conjugating them in hydrophilic nanoparticles that are
functionalized with ligands specific for receptors overexpressed on cancer cell surfaces. Figure
1.6 shows few examples of nanoparticles which are used to encapsulate drug molecules (Figure
1.6 A and Figure 1.6 C) or conjugated drug molecules (Figure 1.6 B) [50]. Encapsulation or
conjugation of drug entities in nanoparticles has multiple advantages over use of the drug entity
alone. For example, Doxorubicin Encapsulated in Polyethylene-glycol Coated Liposomes, called
as Doxil nanoparticles have enhanced accumulation of doxorubicin and increased circulation
time as compared to free doxorubicin [51].
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A

B

C

.
Figure 1.6 A) Polymeric micelles encapsulating drug molecules, B) Polymers conjugated with
drug molecules, C) liposomes encapsulating drug molecules for improved pharmacokinetics and
pharmacodynamics by active intracellular delivery.[50]. The graph shows extended
pharmacokinetics of nanoparticles over the therapeutic entity alone [52]

Figure 1.7 Increased accumulation of doxorubicin when encapsulated in Doxil as compared to
free doxorubicin.[51]
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Figure 1.7 shows the increased level of doxorubicin in the body of patients when it is
encapsulated in Doxil as compared to free doxorubicin. The increase in accumulation is due to
the high amount of loading of drug in nanoparticles of size 80-90 nm in diameter. The PEG
conjugated on the liposomes increases the circulation time in body. Targeted drug delivery is the
solution to reduce the side effects and it can be achieved by encapsulating the drug entities in
nanocarriers which are targeted towards cancer [50]. Doxorubicin encapsulated in liposome
nanoparticles tagged with PEG and the human monoclonal antibody GAH which reacts to almost
90 % of stomach cancer tissue but not to normal tissue was used in patients with metastatic
stomach cancer[53]. Semiconductor quantum dots, CdSe-ZnS, encapsulated in ABC triblock
copolymer linked with tumor-targeting ligand and PEG were used for drug delivery by Gao et al
[54]. The probe was coated with PEG for better circulation in blood while the triblock polymer
protects the optical properties of Qdots in a broad range of pH. Passive targeted delivery in
prostate cancer was achieved by better circulation of the probe due to PEG. The active targeted
delivery was achieved by conjugating the probe with prostate-specific membrane antigen
(PSMA) monoclonal antibody. Figure 1.8 A shows the development of the probe and Figure 1.8
B shows the uptake of the probe in human prostate cancer cells which express PSMA and cells
which do not express PSMA. Another example of multifunctional nanoparticles for cancer
therapeutics is reported by Liong et al. [55]. In this the superparamagnetic nanocrystals for MR
imaging were encapsulated in silica nanoparticles. Anticancer drug was stored inside the pores in
silica. For hydrophilicity the silica nanoparticles were coated with phosphonate coating. The
nanoparticles were made targeted by attaching targeted ligand, folic acid. Figure 1.9 shows
increased uptake of nanoparticles conjugated with folic acid in PANC-1 which overexpresses
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folate receptors. In HFF cells which do not overexpress folate receptors have shown to uptake
fewer nanoparticles.
A

B

Figure 1.8 A) Development of the Qdot probe and depiction of passive (conjugated with PEG)
and active (conjugated with PEG and PSMA antibody) tumor targeting, B) uptake of Qdot probe
in PSMA positive cells (C4-2) and PSMA negative cells (PC-3). A negative control with Qdots
not conjugated with PSMA antibody is also shown

Figure 1.9 Uptake of silica nanoparticles in Panc-1 cells which overexpress folate receptors and
HFF cells which have no folate receptor overexpression.
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Drugs such as paclitaxel, doxorubicin, and STAT3 inhibitor have been used to treat cancer
through chemotherapy [24, 26-28, 49]. These drugs affect the tumor growth by interfering
processes such as mitosis or DNA synthesis which are necessary for proliferation. But during
this, the normal tissue also gets affected as the drugs cannot distinguish between the tumor cells
and the rapidly dividing cells. This causes a lot of side effects. Paclitaxel causes side effects such
as nausea and vomiting, loss of appetite, change in taste, thinned or brittle hair, pain in the joints
of arms or legs, changes in the color of the nails, and tingling in the hands or toes. Doxorubicin
also has a severe side effect, cardiotoxicity [21-23, 56] along with various side-effects such as
acute vomiting and nausea, gastrointestinal problems, baldness, disturbances in the neurological
system leading to hallucination and light-headedness [23].

1.1.3.3 Nanoparticles in Biosensors
Nanoparticles have been developed as biosensors which are used to quantify events inside the
cells such as, release of drug from nanocarriers or interaction of biomolecules with the drug at
the molecular level [57]. Biosensors can also be used to differentiate cancer cells from normal
cells. Biosensors using surface resonance plasmonics have been reported to have multiple uses.
Diverse nanostructures have been exploited for achieving optimal localized surface plasmon
resonance (LSPR) nanosensors [58]. The exquisite sensitivity of the LSPR nanosensors to size,
shape and environment can be harnessed to detect molecular binding events and changes in
molecular conformation [59]. Intracellular molecular imaging using multifunctional gold
nanoparticles which incorporate both cytosolic delivery and targeting moieties on the same
particle is studied to utilize these intracellular sensors monitor the actin rearrangement in live
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fibroblasts [60]. A strong molecular specific optical signal associated with effective targeting of
actin filaments was observed (Figure 1.10).

Figure 1.10 Labeled actin filaments in NIH3T3. [60]

The well-studied biotin-streptavidin system was investigated by Haes et al. by exposure of
biotin-functionalized Ag nanotriangles to 100 nM streptavidin. They observed that the LSPR
λmax red shifted by 27 nm after the interaction of biotin on Ag nanoparticles with the streptavidin
[61]. The use of surface plasmon resonance property of gold nanoparticles as biosensors is also
done to recognize cancer cells from normal cells. El- Sayed et al. have used anti-EGRF
conjugated and non-conjugated gold nanoparticles to distinguish cancer cells from normal cells
by observing the specific and non-specific uptake in the cells. They observed that there was a
14

broadening in the red region of the SPR spectrum of non-conjugated gold nanoparticles due to
aggregations caused by non-specific uptake. Thus observing the SPR spectra of the gold
nanoparticles it was possible to distinguish between specific and non-specific uptake (Figure
1.11) [62].

Figure 1.11 Surface resonance plasmon of gold nanoparticles for diagnosing cancer cells by
conjugating the gold nanoparticles with anti-EGFR.[62]

Carbon nanotubes and graphene have also been studied in different fields of biosensor such as
electrical, optical and electrochemical biosensors and have been found to be very promising
candidates for queries such as diagnosis of life-threatening diseases to detection of biological
agents in warfare or terrorist attacks [63]. Magnetic nanoparticles have been used for detection of
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biomolecules and cells based on magnetic resonance effects using a general detection platform
termed diagnostic magnetic resonance (DMR). DMR technology encompasses numerous assay
configurations and sensing principles. To date magnetic nanoparticle biosensors have been
designed to detect a wide range of targets including DNA/mRNA, proteins, enzymes, drugs,
pathogens, and tumor cells. The core principle behind DMR is the use of magnetic nanoparticles
as proximity sensors that modulate the spin-spin relaxation time of neighboring water molecules,
which can be quantified using clinical MRI scanners or benchtop nuclear magnetic resonance
(NMR) relaxometers [64]. Optical biosensors using fluorescence resonance energy transfer
(FRET) for detection or sensing are getting a lot of attention these days [65].

.
Figure 1.12 Detection of zinc metal ions by FRET [66]

FRET has been used in carefully designed sensing systems for proteins, peptides, nucleic acids
and small molecules [66-70]. Another example is the detection of ions in the intracellular
environment. A FRET scheme was used to detect Zn+ by Hellinga et al. Figure 1.12 shows how
the zinc sensor is based on the zinc finger (ZF) peptide. When zinc (purple) gets bound by a
His2Cys2 primary coordination sphere in the folded ZF, the ZF undergoes a folding transition
which can be monitored either by FRET between donor (yellow) and acceptor (red) fluorophores
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located at the N- and C-termini of the peptide2 or by changes in the microenvironment of a
fluorophore located in the hydrophobic core (green) [66].
Recent advancements in the developments of luminescent quantum dots (Qdots) for FRET based
sensing probes are highly promising in detecting molecular level changes in biological systems.
Qdots luminescence property has also been used in sensing proteins. As seen from Figure 1.13
Qdots which are conjugated to protein which have 5 and 11 C-terminal hystidines and the apomyohystidine has produced fluorescence. The protein which has 0 C- terminal does not produce
any

fluorescence,

thus

sensing

only

particular

proteins

[71].

Figure 1.13 Attachment of particular proteins to Qdots produces fluorescence of Qdots [71]

Shan Huang el at. have used the Qdots fluorescence ON-OFF property to detect the ruthenium
anticancer drug and the calf thymus DNA (ctDNA) [72]. Fluorescence of CdTe Qdots is
quenched by ruthenium anticancer drug due to its surface binding on CdTe Qdots. The
photoinduced electron transfer (PET) process from Qdots to ruthenium drug put the Qdots in
OFF state. ctDNA was detected by these OFF state Qdots. As ruthenium anticancer drug broke
away from the Qdot surfaces and were inserted into the double helix structure of ctDNA due to
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which the PET was hindered between ruthenium drug and Qdots and the fluorescence of Qdots
was restored (Figure 1.14).

Figure 1.14 Detection of ruthenium anticancer drug and ctDNA with Qdot fluorescence ON-OFF
process. [72]

Similarly, CdSe-ZnS Qdots have been used by Medintz et al. for pH sensing in cells [73]. In this
the Qdots were assembled with peptide-dopamine conjugates. The dopamine is in pre-reduced
form, that is, hydroquinone form which is a poor electron acceptor. At low pH hydroquinone is
the

predominant
A

form.

Due

to

this

low

Qdot

fluorescence

quenching

occurs.

B

Figure 1.15 Qdot-dopamine probe for pH sensing. A) model of the probe and electron transfer
processes which quenches the fluorescence of Qdots at high pH, B) fluorescence intensity of
Qdots with decreasing pH. [73]

18

As the pH is increased, due to ambient O2 in the buffer hydroquinone is oxidized to quinone
which is a good electron acceptor. This causes higher quenching of Qdot fluorescence. Figure
1.15 A shows the model of Qdot pH sensor and the shuttling of electrons between dopamine and
Qdots. Figure 1.15 B shows the increase in fluorescence intensity of Qdot with decreasing pH.

1.1.4 Photodynamic Therapy for cancer treatment
Photodynamic therapy (PDT) is an emerging promising treatment for cancer [74-79]. In this
therapy a photosensitizing agent is injected into the body and is irradiated with a particular
wavelength of light. By absorbing this light of a particular wavelength it produces a form of
oxygen that kills nearby cells [75, 78, 79]. The wavelength used to activate the photosensitizer
determines how far the light can travel through the body [77, 78]. Thus, to treat different areas of
the body through PDT, specific photosensitizers and wavelengths of light are used. In addition to
killing the cancer cells PDT can work in two more ways [75, 76, 78, 79]. It can destroy the blood
vessels on the tumor, thus depriving the cancer tissue from getting any nourishment. Also, it can
activate the immune system to destroy the tumor. To treat cancer inside the body through PDT
the photosensitizer can be activated by laser which can be delivered through fiber optic cables
(thin fibers that transmit light) [79]. For example, a fiber optic cable can be inserted through an
endoscope (a thin, lighted tube used to look at tissues inside the body) into the lungs or
esophagus to treat cancer in these organs. For surface tumors such as skin cancer normal light
emitting diodes can be used [77].
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1.1.4.1

Mechanism of PDT

The mechanism by which the harmful oxygen species are generated through PDT involves
photoexcitation of the photosensitizer leading to the formation of triplet excited states via
intersystem crossing from singlet excited states. These triplet states can dissipate via two types of
photooxidative pathways. In type I photooxidation the photosensitizer transfers charge or energy
to the ground state of molecular oxygen to give rise to the reactive superoxide radical or to the
biomolecules and solvent molecules in the cells. In type II photooxidation the triplet state of the
photosensitizer transfers energy to the triplet ground state of oxygen to form singlet oxygen [76,
80-83] (Figure 1.16). These processes can occur simultaneously once the photosensitizer in
photoactivated. The ratio between these processes depends on the type of the photosensitizer
used, the concentrations of substrate and oxygen, and the binding affinity of the photosensitizer
for the substrate. The half-life of singlet oxygen in biological systems is <0.04 μs, and, therefore,
the radius of the action of singlet oxygen is <0.02 μm [80, 81, 84]. Thus the extent of cell
damage depends on a lot of factors such as the type of photosensitizer, its extracellular and
intracellular localization, its total dose administered, the total light dose, oxygen availability, and
the time between the administration of the drug and light exposure. For PI1 photosensitization of
cells in vitro, full effects are observed at about 5% O2 levels, when the oxygen is reduced to 1 %,
the effect is also halved [81]. No photosensitization can be observed in the absence of
measurable oxygen which was observed to be true when Gomer and Razum performed an
experiment in which PDT was applied to induced tissue hypoxia in vivo by clamping. There was
no PDT effect on the tissue [85].
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Figure 1.16 Type I and Type II photooxidation pathways in PDT [83]

The reactive species of oxygen formed via type I and type II processes after photoactivation of
the photosensitizer react further in different ways to form molecules like hydroxyl radical and
hydrogen peroxide which are highly reactive. The singlet oxygen and the oxygen species formed
in the photochemistry of the photosensitizer are called as Reactive Oxygen Species (ROS). These
ROS induce an oxidative stress in the cells through lipid peroxidation and the cells die.
The superoxide radical (O2-) formed in the type I photooxidation can grab an electron and form
peroxide ion (O22-) which gets protonated quickly at the physiological pH to form hydrogen
peroxide (H2O2). The overall reaction is,
2O2- + 2H+

H2O2 + O2

……………………………….Reaction (1)

The superoxide also reduces Fe (III) to Fe (II). This is called as Fenton reaction
O2- + Fe3+

Fe2+ + O2

……………………………….Reaction (2)
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The hydrogen peroxide formed in reaction (1) forms hydroxyl radicals in presence of Fe (II)
formed in reaction (2). Thus transition metal ion dependent OH· formation is O2- stimulated [86].
Fe2+ + H2O2

Fe3+ + OH· + OH-

……………………….Reaction (3)

The hydroxyl radical ions formed in the reaction (3) abstract a proton from any biomolecule
(lipids) and a lipid radical is formed. This lipid radical reacts with the molecular oxygen to form
lipid

peroxide

OH· + L-H
L· + O2
LOO· + L-H

which

leads

to

a

chain

reaction

of

lipid

peroxidation.

L · + H2 O
LOO·
LOOH + L·

…………………………..Reaction (4)

Another way of lipid peroxidation is reaction between the singlet oxygen formed in the type II
photooxidation and the lipid molecules. This reaction cannot be considered as the initiation of
the lipid peroxidation chain reaction, because the singlet oxygen does not abstract a proton to
give rise to a radical. It directly reacts with lipid molecules to form lipid peroxide [86].
1

O2 + L-H

LOOH
………………………………………Reaction (5)

1.1.4.2

Small molecules for PDT

Different kinds of photosensitizers are used in PDT. Few of the photosensitizer examples are 1)
pthalocyanines, 2) chlorines such as mTHPC (meta tetrahydroxyphenyl chlorin), 3) porphyrines
such as BPD (benzoporphyrine derivative), HP (hematoporphyrin), HPD (hematoporphyrin
derivative), 4) azulene, 5) erythrosine, 6) 5-ALA (5-aminolevulinic acid). Porphyrines are the
most studied photosensitizers to date. They have a general structure of four pyrrole rings
22

connected with methylene bridges in a cyclic fashion and a metallic side chain. HPD, tin ethyl
etiopurpurin (Purlytin) and motexafin lutetium were used as photosensitizers to treat breast
cancer in patients [87-89]. Gynecological cancers have also been treated with different
photosensitizers such as 5-aminolevulinic acid, HPD using PDT [90-92]. Patients with
gastrointestinal tumors were treated with three photosensitizers – ALA, photofrin and mTHPC
and red light using light dose depending on the photosensitizer (10-15 J/cm2 for mTHPC and 50150 J/cm2 for ALA and photofrin) [93]. Intraperitoneal malignancies in patients were treated
with dihematoporphyrin ethers (DHE) and irradiated with green light for PDT [94]. All these
photosensitizers were administered into the patient bodies either by intravenous or orally and
then light was irradiated on the tumor area. Patients with pancreatic cancer were treated with
mTHPC and light was delivered using fibers to induce necrosis in the malignant tissue [95].
These photosensitizers are directly absorbed in the cancer cells.

1.1.4.3

Nanoparticles for PDT

Most of the photosensitizers are hydrophobic and pose problems such as prolonged cutaneous
photosensitivity and selectivity. These problems can be overcome by incorporating the
photosensitizer in the nanoparticles. This can be done by enveloping the photosensitizer inside
the nanoparticles wherever necessary and by reducing the hydrophobicity by attaching the
photosensitizer to a hydrophilic nanoparticle. The incorporation of photosensitizer in
nanoparticles can be achieved in two ways: 1) conjugation of the photosensitizer to the NPs, and
2) encapsulation of the photosensitizer inside the NPs. Examples of NPs which carry
photosensitizers are organic NPs, inorganic NPs, polymeric NPs, micelles, liposomes. In the
inorganic type NPs silica coated gold NPs were found to be very efficient in delivering chlorin
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e6 (Ce6) photosensitizers in MDA-MB-435 cells. These AuNCs@SiO2-Ce6 NPs showed an
improved PDT efficacy as compared to free Ce6 as shown in Figure 1.17 [96].
A

B

Figure 1.17 A) fluorescence of free Ce6 and Ce6 conjugated with gold NPs (AuNCs@SiO2.Ce6)
in MDA-MB-435 cells showing that the Ce6 photosensitizer is efficiently delivered in cells when
conjugated with NPs as compared to free Ce6, B) cell viability of MDA-MB-435 administered
with free Ce6 AuNCs@SiO2.Ce6, with and without light.[96]

Similar observation was done by Ito et al. when 5-ALA and 5-ALA-Me was incubated with
MCF-7 and HepG2 cell lines in presence and absence of citrate capped gold NPs (AuNPs). They
found that the cell damage was a factor of 1.5 more in presence of AuNPs as compared to 5ALA alone [97]. Mannose functionalized silica coated magnetic nanoparticles encapsulating
porphyrin photosensitizer were used by Perrier et al. for PDT [98], while photosensitizer tetrasubstituted carboxyl aluminum phthalocyanine (AlC4Pc) covalently linked to the mesoporous
silica shell and superparamagnetic nanoparticles at the core were studied by Wang et al. [99].
Silica

nanoparticles

encapsulating

the

photosensitizing

drug

2-devinyl-2-(1-

hexyloxyethyl)pyropheophorbide (HPPH) were used in PDT to kill HeLa cells [100]. In another
example of silica NPs a third-generation (G3) polyamidoamine (PAMAM) was grafted to the
surface of porous hollow silica nanoparticles followed by the attachment of gluconic acid (GA)
for surface charge tuning. The PAMAM-functionalized outer layer with a large number of amino
24

groups allowed high loading efficacy of the photosensitizer aluminum phthalocyanine
tetrasulfonate (AlPcS4). These silica NPs conjugated with the photosensitizer were studied in
MCF-7 cell lines and were observed to have higher efficiencies in killing the cells through PDT
as

compared

to

free

photosensitizer

as

shown

in

Figure

1.18

[101].

Figure 1.18 Cell viability of MCF-7 with free AlPcS4 and silica NPs conjugated with AlPcS4
showing that the efficacy of PDT was increased due to better delivery of the photosensitizer
through silica NPs in cells [101]

Photosensitizer AlC4Pc was covalently conjugated to a mesoporous silica network to deliver the
photosensitizer in HeLa cells [102]. Organically modified silica nanoparticles encapsulating the
hydrophobic photosensitizer HPPH for PDT were also developed by Ohulchanskky [103]
(Figure 1.19). Polymeric NPs like Poly[2-methacryloyloxyethyl phosphorylcholine-co-n-butyl
methacrylate-co-p-nitrophenylcarbonyloxyethyl methacrylate] (PMBN) doped with vertiporfin
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as the photosensitizer to study PDT in A431 cells [104] and polymeric micelles of block
copolymer poly(ethylene glycol)–co-poly(D,L-lactic acid) (PEG-PLA) loaded with 5,10,15,20tetrakis(mesohydroxyphenyl)porphyrin (mTHPP) as the photosensitizer have been reported
[105]. Liposomes doped with various photosensitizers have been studied for application in PDT
[106].

Phthalocyanine

phthalocyanine

conjugated

decorated

polypropylenimine

dendrimers

[107,

108]

dendrimers,

and

have

been

also

porphyrine
reported.

Figure 1.19 Encapsulation of photosensitizer in organically modified silica nanoparticles for
effective delivery of the sensitizer [103]

Recently, photosensitizer-doped conducting polymer nanoparticles have received attention as
potential photosensitizers for PDT. Photosensitizer tetra-phenylporphyrine (TPP) doped
conjugated polymer poly(9,9-dihexylfluorene) PDHF nanoparticles were developed and
characterized by Grimland et al. [109]. The polymer has a high two photon cross section which
makes it a promising candidate for near infrared multiphoton photodynamic therapy. In this the
nanoparticles absorb light and transfer energy efficiently to the TPP photosensitizer producing
high amounts of singlet oxygen (Figure 1.20). The formation of singlet oxygen was proved by
UV-vis spectroscopy.
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Figure 1.20 Energy transfer process in conjugated polymer PDHF doped with TPP
photosensitizer and the absorbance and emission spectra of the undoped and doped conjugated
polymer nanoparticles. The blue spectrum is the emission of undoped PDHF polymer while the
red spectrum is the emission of the doped PDHF nanoparticles. The emission of the polymer is
reduced to background due to energy transfer to TPP. [109]

DNA damage as a proof-of-concept for formation of singlet oxygen was shown by these authors
1.21)

(Figure

[109].

Figure 1.21 Electrophoresis gel image showing DNA damage by NPs-generated ROS. Lane 1: 1
kb Mw ladder, lanes 2–4: plasmid DNA; DNA + H2O2 (50 mM); DNA + Fe2+ (2 mM) + H2O2.
Lanes 5–8:DNA + nanoparticles irradiated for 0, 50, 100 and 200 min, respectively. [109]

Shen

et

al.

concurrently

encapsulated

TPP

in

conjugated

dibromohexylfluorene-2,7-ylenethylene-alt-1,4-(2,5-dimethoxy)
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polymer,

phenylene]

poly[9,9-

(PFEMO)

and

proved the formation of singlet oxygen by singlet oxygen luminescence [110]. The two-photon
excitation properties of TPP were enhanced by the PFEMO
There are examples in which NPs are developed in such a way that they themselves act as a
photosensitizer when photoirradiated inside the cells. The inorganic type of such NPs includes
quantum dots [111, 112], gold nanorods (Au NRs) [113]. Nano titanium oxide nanoparticles
were used to see the effect of PDT on human keratinocyte HaCaT cells and it was observed that
the cell viability reduced with increase in dose of NPs [114].
A lot of work has been done on targeting cancer cells with different ligands to make PDT more
specific, that is, solving the problem of selectivity for photosensitizers so as to reduce the side
effects by avoiding the uptake of photosensitizers in normal cells (Figure 1.22).

Figure 1.22 Folate receptors mediated uptake of nanoparticles conjugated with folic acid.

Recently PDT using Fe3O4/Au NPs attached with 5,10,15,20-tetrakis(4-hydroxyphenyl)21H,23H-porphine (tHPP) as a photosensitizer and affibody for Her-2 specificity to target SKOV-3 cells was studied [115]. These NPs were tested in xenografted tumor also and were found
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to be very effective in showing specificity and inhibiting the growth of the tumor as compared to
the NPs which were not attached with the affibody peptide. EGFR targeted PDT using liposomes
attached with cetuximab as the targeting antibody and BPD as photosensitizer in ovarian cancer
cells gave very promising results [116]. Conjugation of folic acid for selective delivery of
photosensitizer in different types of cancer tissues is also well documented and is still in
progress. Polymeric micelles conjugated with folic acid to deliver meta - tetra
(hydroxyphenyl)chlorin (mTHPC) in xenografted KB cells in vitro and in vivo is studied by Syu
et al.[117]. CdTe quantum dots acting as a photosensitizer and conjugated with folic acid for
specificity were studied by Morosini et al. in KB cells as folate receptor (FR) overexpressing
cells [118]. Zinc tetraaminophthalocyanine (ZnaPc) with high cross section for two-photon
excitation conjugated with folic acid to observe the selective delivery of the photosensitizer to
FR positive KB cells and FR negative A549 cells showed that the ZnaPc-FA is a promising
candidate for PDT [119]. Graphene oxide nanoparticles loaded with photosensitizer chlorin e6
(Ce6) and conjugated with folic acid were used in PDT to see the effect on MGC803 cells [120].
These nanocarriers were showed to have great potential as efficient drugs in PDT.

1.2

Significance of Research

Efficient and effective treatment involves the drug or the photosensitizer to be delivered in
correct amounts, at correct sites of malignancy without causing any side effects. Such a treatment
can be achieved by using hydrophilic drugs and sensitizers, which can stay in the blood
circulation for longer time, and are efficiently and selectively uptaken by cancer cells while
avoiding normal cells. Unfortunately, drugs and photosensitizers are usually hydrophobic and
non-selective between normal and cancer cells. Treatment is often less efficient and causes a lot
29

of side effects by affecting the healthy tissue due to these issues. In addition, patients that
underwent PDT show prolonged cutaneous photosensitivity, which is an unresolved issue with
PDT.

1.2.1

Conjugated polymer and fullerene doped/blended conjugated polymer nanoparticles

1 Hydrophilic drugs usually remain in circulation until excreted, while being uptaken slowly by
cells. However, most pharmaceuticals for cancer treatment are hydrophobic, which causes poor
circulation in the blood stream and ineffective delivery. Hydrophobic compounds tend to leak
out of the porous tumor vasculature and are retained in tumor tissue, where aggregation takes
place [121, 122]. Under these circumstances the uptake of drug by tumor cells is severely
limited. The hydrophobicity issue is addressed here for PDT photosensitizers by fabricating
nanoparticles out of conjugated polymers. This approach was motivated by the hypothesis that
conjugated polymers themselves can act as photosensitizers, without the need to blend or
functionalize with common small molecule photosensitizers. As the conjugated polymer itself is
hydrophobic, during the fabrication of nanoparticles by the reprecipitation method the polymer
aggregates away from water to form nanoparticles. These nanoparticles are water dispersible and
the solution is a suspension of nanoparticles in water (like oil in water emulsion). It is stable in
cell culture media. Thus the controlled aggregation of the conjugated polymer by preparing
nanoparticles out of it makes the polymer accessible in the cells without aggregating further in
the tumor tissue.
2. The circulation time in blood is improved and made longer by blending the conjugated
polymer with a comb-like amphiphilic polymer PS-PEG-COOH (Polystyrene Graft Ethylene
Oxide with carboxylic acid) having hydrophobic backbone made of polystyrene and poly30

ethylene glycol (PEG) side chains terminating in carboxylic acid groups. PEG has been shown to
increase circulation time in the blood stream [123, 124]. The nanoparticles fabricated out of this
blend have a core of hydrophobic conjugated polymer mixed with polystyrene backbone. The
PEG side chains with the carboxylic acid groups point towards water due to their hydrophilicity.
This further increases the water dispersibility of the conjugated polymer and increases the blood
circulation time.
3. Theoretically, significant drug concentrations in diseased compartments of the body should be
achieved without distributing the drug throughout healthy tissue. In practice, due to limited
circulation times, drug hydrophobicity and lack of selectivity to disease targets, only limited
amounts of drug reach the intended site. Because of this, larger amounts of drugs than necessary
must be applied, which causes the healthy tissue to get affected by the adverse effects of the
cytotoxic drugs. Many promising pharmaceuticals have failed clinical trials due to these issues.
Strategies to efficiently and selectively deliver photosensitizer and drugs to target sites have
therefore received tremendous attention in the field with the aim to overcome these issues and
reduce cytotoxicity related side effects [121, 122]. This is achieved here by conjugating the
polymer nanoparticles with ligands which can bind to specific receptors overexpressed on the
cell surface of cancer cells. Cancer cells overexpress receptors such as folate receptors (FR),
epidermal growth factor receptors (EGFR), Her-2 receptors and others depending on the type of
cancer. Ligands specific towards these receptors such as folic acid (FA), antibodies Erbitux or
Cetuximab and affibody respectively can be used to target particular types of cancer. Here folic
acid has been used to functionalize the nanoparticles and target them towards the cell lines which
overexpress folate receptors on their surfaces. The carboxylic acid groups from PS-PEG-COOH,
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which are protruding out on the surface of the nanoparticles were modified to conjugate folic
acid through the traditional EDC chemistry.
4. After delivering the drug or photosensitizer in the cells it is necessary to have the knowledge
of its course of action in the cells. To have a safer and efficient treatment the measurements on
events such as amount of drug released from the nanocarriers in the cells, amount of drug getting
used up in the cells, time needed to release the drug in the cells are essential. Specifically,
knowledge on the localization of photosensitizer for PDT in tissue is necessary to evaluate
potential effectiveness of PDT treatment and dispersion of the photosensitizer throughout healthy
and diseased tissue. The latter is important for unresolved issues with PDT such as prolonged
cutaneous photosensitivity. As the conjugated nanoparticles are highly fluorescent, they can be
easily tracked at the particle level and their localization in the cells, whether those are in
endosomes, lysosomes or in cytoplasm can be known.
5. Along with hydrophobicity and non-selectivity, photosensitizers like vertiporfin, 5aminolevulinic acid, methyl 5-aminolevulinic acid and photofrin have substantial problems with
prolonged cutaneous photosensitivity of patients [125, 126]. Cutaneous photosensitivity causes
skin diseases showing symptoms such as pigmentation and phototoxic reactions including itchy
or burning sensation, erythema and swelling. Cutaneous photosensitivity can be avoided by
encapsulating the photosensitizer drugs into nanocarriers that can carry the drug to the required
tumor tissue. Only when the photosensitizer is released from the nanocarrier in the intracellular
environment ROS will be formed. As the conjugated polymer itself acts as a photosensitizer
here, the use of any additional photosensitizer is not needed for the PDT, which in turn avoids
the possibility of photosensitivity caused by these photosensitizers. However, at this time it is not
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known if prolonged cutaneous photosensitivity could be caused by the conjugated polymer
nanoparticles.

1.2.2 Quantum dot biosensors for drug delivery, quantification and drug discovery

A lot of work has been reported on delivering drugs in cells via nanocarriers such as inorganic
nanoparticles, polymeric nanoparticles, liposomes, and dendrimers. But little is known about the
delivery and release events of a drug from the nanocarriers in the cells. Whether or not the
nanocarriers with drug actually entered the cell, the location of drug release in the cell, the time
required for drug release and the amount of drug released are questions that have often remained
unanswered. These are important questions that need to be addressed in order to develop
effective, safe and efficient drugs. A biosensor that can selectively and effectively carry drug to
the target site, report on the event of drug release inside the cells, can provide the location of
drug release, and can quantify the amount of drug released is needed. Such a biosensor would not
only provide a way to improve treatment efficiency, but would also bring a paradigm shift in the
field of drug discovery.
Here a biosensing probe was developed for which the core functionality consists of fluorescence
quenching and restoration of Qdots upon conjugation and release of a ligand, respectively. Drug
was attached to the ligand for delivery by the Qdots biosensor. A biocompatible polymer shell
was decorated with targeting ligand for selective delivery, PEG for improved water dispersion
and circulation time in the blood stream, and a fluorescent dye for ratiometric quantification of
the amount of drug that is delivered

33

The ligand used here is dopamine, which was conjugated to CdS:Mn/ZnS Qdots through a zero
length linker molecule such as carbon disulphide (CS2). Upon conjugation, the fluorescence of
Qdots is quenched (OFF probe) due to charge transfer between dopamine and Qdots. The
transfer of electrons occurs to or from Qdots depending on the oxidation state of dopamine When
the OFF probe enters the cytosolic environment in the cells, the glutathione present in the
cytoplasm displaces the CS2-dopamine(-drug) conjugates from the Qdots surfaces and
fluorescence is restored (ON probe). Therapeutic drug (STAT3 inhibitor) is attached to the
dopamine ligand and is thus released from the probe upon delivery in the intracellular
environment and the fluorescence of the Qdots is restored. The quantification of release of drug
in the cells is achieved by ratiometric measurement on the fluorescence of Qdots (variable by
amount of ligand released) in the ON state with respect to the constant emission of dye in the
chitosan shell. By measuring the ratio of the dye fluorescence which stays constant to the
fluorescence of Qdot (which depends on the release of the drug), the amount of drug released in
the cells can be calculated.
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CHAPTER 2

2.1

INSTRUMENTATION AND EXPERIMENTALS

Introduction

To make the drugs used in therapeutics for cancer more effective towards curing the cancer, it is
necessary to understand how they work in body. To understand this it is essential to learn their
properties and mechanism of action in-vitro before introducing them in-vivo. This was achieved
by growing cell lines in lab and performing experiments on them for in-vitro studies. Conjugated
polymer nanoparticles were fabricated and characterized to study their applications as the next
generation photosensitizers in photodynamic therapy. Functionalization of nanoparticles with
folic acid as targeting agent towards folate receptor expressing cell lines was achieved to make
PDT targeted thus reducing the side effects by avoiding uptake in healthy cells. The cell
viabilities after PDT were quantified by MTT and MTS assays and were confirmed by flow
cytometry experiments which are discussed in detail here within. Fluorescence microscopy
including confocal and epiluminescence were used for imaging purposes. Single Particle
Spectroscopy (SPS) was performed to confirm the uptake and stability of nanoparticles in cells.
In the case of Qdot-dopamine biosensor probe the restoration of Qdot fluorescence was
confirmed by SPS and confocal microscopy. All the experimental details have been discussed in
the following subsections.

2.2

Nanoparticle fabrication
2.2.1 Doped NPs and CPNPs fabrication

Poly[2-methoxy-5-(2-ethylhexyloxy)-1,4-phenylenevinylene]

(MEH-PPV)

with

molecular

weight 150,000-250,000 g/mol (average Mn, PDI- 2.2) was purchased from Sigma Aldrich and
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used without any further purification. Phenyl-C61-butyric acid methyl ester (PCBM) was
purchased from Sigma-Aldrich and was used as is. THF (tetrahydofuran, Drisolv) was purchased
from EMD. The nanoparticles were fabricated following our previously published protocol. [127,
128]. In short, for CPNPs 1 mg MEH-PPV was dissolved in THF and was diluted to a 10 -6 M
concentration by using absorbance and Lambert-Beer law. 1ml of this solution of MEH-PPV in
THF was quickly injected into 4 ml of DI water under vigorous stirring. Stirring was stopped
immediately after injection of the polymer solution in water. While for doped NPs a blended
solution containing a 1:1 mass ratio of the conjugated polymer MEH-PPV and the fullerene
PCBM was prepared in THF and diluted further to get 10-6 M concentration of MEH-PPV. 1 ml
of this solution was quickly injected in 4 ml water. Due to hydrophobicity the polymer and
fullerene aggregated away from water to form nanoparticles. The structures of MEH-PPV and
PCBM and the reprecipitation method of fabrication of nanoparticles are shown in Figure 2.1A
and B.

A

B

Figure 2.1 A) chemical structures of MEH-PPV and PCBM, B) reprecipitation method of
nanoparticle fabrication. The stirring was done at 1200 rpm. As soon as the injection was
completed the stirring was stopped immediately.

36

2.2.2 FNPs fabrication
2.2.2.1

Preparation of MPNPs

Poly[2-methoxy-5-(2-ethylhexyloxy)-1,4-phenylenevinylene]

(MEH-PPV)

with

molecular

weight 150,000-250,000 g/mol (average Mn, PDI-2.2) was purchased from Sigma Aldrich and
was purified to remove the low molecular weight polymer chains. Comb-like polymer
Polystyrene Graft Ethylene Oxide with carboxylic acid (PS-PEG-COOH) with molecular weight
36500 g/mol (average Mn, PDI-1.3) was purchased from Polymer Source Inc and used as is.
THF (tetrahydofuran, Drisolv) was purchased from EMD.
2.2.2.1.1 Purification of MEH-PPV
For purification 6 ml of HPLC grade acetone (Sigma Aldrich) was added to 3 mg MEH-PPV in a
vial. The vial was heated gently at a low temperature on a hot plate to obtain yellow supernatant,
which was removed using a glass pipette without removing the MEH-PPV at the bottom of the
vial. A small amount of chloroform (approximately 3 ml) (Sigma Aldrich) was added to this vial
to dissolve MEH-PPV. In this orange solution acetone was added in 1:5 ratio of
chloroform:acetone. This suspension was transferred to a centrifuge tube and centrifuged for 10
minutes at 4000 rpm. The high molecular weight MEH-PPV settles at the bottom while the low
molecular weight MEH-PPV remains in the supernatant. The supernatant was removed and the
procedure was repeated until the supernatant turn light pink colored (4 repetitions were needed).
The purified MEH-PPV was covered with a parafilm, small holes were punctured in it and dried
overnight.
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2.2.2.1.2 Fabrication of MPNPs
1mg purified MEH-PPV was dissolved in 3ml THF to obtain 0.33 mg/ml stock solution of MEHPPV and 1mg PS-PEG-COOH was dissolved in 50 ml THF to obtain 0.02 mg/ml stock solution
of PS-PEG-COOH separately. To obtain 2:1 molar ratio 1 ml of MEH-PPV stock solution was
mixed with 1ml PS-PEG-COOH stock solution and was diluted further with THF to 10-6 M
concentration of MEH-PPV. 1 ml of this diluted solution was quickly injected into 4ml of DI
water under vigorous stirring. Stirring was stopped immediately after injection of solution into
water. Due to hydrophobicity the MEH-PPV and PS backbone of the non-fluorescent polymer
self-aggregate to form nanoparticles. The hydrophilic PEG and COOH parts of the polymer
extend towards water, now available for further functionalization by folic acid. The solution
obtained is a suspension of MPNPs (MEH-PPV—PS-PEG-COOH blended Nanoparticles) in
water and was used for functionalization with folic acid.
2.2.2.2 Functionalization by EDC chemistry
For functionalization the carboxylic groups on the MPNPs surfaces were activated by NHydroxysuccinimide

(NHS)

and

N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide

hydrochloride (EDC) purchased from Sigma Aldrich. Excess NHS was added to 15 ml MPNPs
suspension in water. After 15 minutes of stirring excess EDC was added to this solution. The
solution of MPNPs, NHS and EDC was stirred again for 15 minutes. 1:1 molar ratio of PS-PEGCOOH:folic acid (Sigma Aldrich) was used for the final functionalization step and stirred for 2
hours. The solution obtained is unfiltered folic acid functionalized nanoparticles (FNPs).

38

2.2.2.3 Centrifugal filtration
15 ml of FNPs were filtered by centrifugal filtration to remove the unreacted folic acid, NHS and
EDC from the nanoparticle solution. Amicon Ultra-15 Centrigugal Filter Devices with Molecular
Weight Cutoff 10,000.was used for filtration. The solution was spun at 4000 x g in swinging
bucket rotor for 60 minutes. To remove the unreacted NHS, EDC and folic acid from the FNPs
solution, 6 to 7 filtrations were needed. After each filtration cycle approximately 3ml of filtrate
was removed. After each filtration the volume of the FNPs solution was adjusted back to 15 ml
by adding DI water, effectively replacing the unreacted folic acid, NHS and EDC from the
solution with DI water. Progress was monitored by Uv-vis and fluorescence spectroscopy
completed for each filtrate as shown in Figure 2.2A and B
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Figure 2.2 Centrifugal filtration for washing functionalized nanoparticles tracked by A) UV-vis
and B) fluorescence spectroscopy. All the unreacted folic acid, NHS and EDC were removed
from the FNPs suspension during 6th or 7th filtration as seen from fluorescence spectra of folic
acid after which there is no change in the intensity of folic acid emission. Excitation wavelength
is 350 nm.
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2.3

Characterization of nanoparticles
2.3.1 DLS, TEM, AFM for size determination

2.3.1.1 Dynamic light scattering (DLS)
The size of the nanoparticles was determined with a Precision Detector Dymanic Light
Scattering (PD2000DLS) machine. Data was analyzed using the Precision Deconvolve software.
For doped NPs and CPNPs the nanoparticle suspension was diluted by adding 50 µl of
nanoparticle suspension into 3 ml of DI water in a quartz cuvette of 1 cm path length. For FNPs
size of nanoparticles was measured the same way after each centrifugal filtration.
2.3.1.2 Transmission electron microscopy (TEM)
The diameter of the doped NPs and CPNPs was determined using transmission electron
microscopy (TEM, Phillips Tecnai F 30). A drop of the nanoparticle suspension was placed on a
TEM grid and vacuum dried before imaging.
2.3.1.3 Atomic force microscopy (AFM)
Atomic Force Microscopy was run on a Digital Instruments Multimode and Dimension 3100
system with NanoScope IIIa controller. After dilution the same way for DLS, 6 µl of MPNPs,
CPNPs and FNPs suspensions in water were dropped onto freshly peeled mica substrates. These
samples were vacuum dried for 15 min before imaging.
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2.3.2 UV-vis and fluorescence spectroscopy for optical properties
2.3.2.1 UV-vis spectroscopy
The absorption spectroscopy on the nanoparticles suspension in water was completed in a 1 cm
path length quartz cuvette after diluting the suspensions as explained in the DLS section, with an
Agilent 8453 spectrophotometer using the Chemstation software.

2.3.2.2 Fluorescence spectroscopy

The fluorescence spectroscopy on the nanoparticles suspension in water was performed in a 1 cm
path length quartz cuvette after dilution of the suspensions as described in DLS section, with a
NanologTM HoribaJobin Yvon fluorimeter.
2.3.3 FTIR for FNPs
Fourier Transformation Infrared Spectroscopy (FTIR) analysis of FNPs was completed using a
Perkin Elmer Spectrum 100 Series (650-4500 cm-1) FTIR Spectrophotometer. 30 ml filtered
FNPs, MPNPs and CPNPs were frozen in DI water and then lyophilized (FreeZone 4.5L Freeze
Dry System, Labconco) to obtain a powder and FTIR was run on these samples. CPNPs and
MPNPs were run as control experiments.

2.4

Cell culture

All the experiments related to cell culture and in-vitro studies are explained in this section and
subsections. Mostly, incubation of cell lines with different nanoparticles, counting the cells for

41

cell viability assays and flow cytometry is explained. Staining the cells with different dyes for
fluorescence imaging and flow cytometry is covered.
2.4.1 Propagation (maintaining the cell culture)
TE 71 (Mouse thymic epithelial normal cell line) , MDA-MB-231 (Human breast cancer cell
line), MIA PaCa2 (Human pancreatic cancer cell line), A549 (Human lung cancer cell line) and
OVCAR3 (Human ovarian tumor cell line) cell lines were purchased from ATCC and grown in
10 % Fetal bovine serum (FBS) in Dulbecco's Modified Eagle Medium (DMEM), under 5 %
CO2 and humid atmosphere at 370C. Cells were harvested using 0.05 % trypsin in Dulbecco's
Phosphate-Buffered Saline (DPBS)
2.4.2 Nanoparticle uptake studies

For studying the uptake of doped NPs, FNPs and Qdot probes various cell lines were grown upto
40% confluency in 35 mm petri dishes in complete growth medium for 24 hours. For CPNPs the
cells were counted by using hemocytometer and 10,000 cells were added in each well in 96 well
plate and kept in the incubator for 24 hours.
For doped NPs, after growing for 24 hours, TE 71, MDA-MB-231, A549 and OVCAR3 cells
lines were washed with DPBS and incubated with 2 x 10-4 mg/ml doped NPs in DMEM for 24
hours. Then the cells were washed with DPBS for 2-3 times and were fixed with 4 %
paraformaldehyde. After fixing the cells were stained with DAPI nuclear dye. The cells were
suspended in DPBS for imaging.
For CPNPs, increasing concentrations of CPNPs in DMEM (0.4 x 10-4 mg/ml, 2 x 10-4 mg/ml
and 3.6 x 10-4 mg/ml) were added to TE 71, MDA-MB-231, A549, and OVCAR3 cells lines in
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the 96 well plate and incubated for 24 hours. Then the cells were washed with DPBS 2-3 times
and harvested with 0.05 % trypsin. All the cells lines with different concentrations of CPNPs
were added in different petri dishes and incubated for another 24 hours in complete media. Then
the cells were washed for 2-3 times with DPBS and fixed with 4 % paraformaldehyde. After
fixing the cells were stained with DAPI nuclear dye. The cells were suspended in DPBS for
imaging.
For FNPs, TE 71, MIA PaCa2, A549, and OVCAR3 cells lines were incubated with 2 x 10 -4
mg/ml FNPs in complete media for 24 hours. Then the cells were washed for 2-3 times with
DPBS and fixed with 4 % paraformaldehyde. After fixing the cells were stained with DAPI
nuclear dye. The cells were suspended in DPBS for imaging.
For Qdot probe, TE 71, A549 and OVCAR3 cell lines were incubated with 0.05 mg/ml Qdot
probe in DMEM for 24 hours. Then the cells were washed for 2-3 times with DPBS and fixed
with 4 % paraformaldehyde. The cells were suspended in DPBS for imaging.
2.4.3 MTT and MTS viability assays
For doped NPs and CPNPs MTT viability assay was used to evaluate the intrinsic cytotoxicity of
the nanoparticles and the effect of PDT in different cell lines. For FNPs MTS viability assay was
used for the same reasons. There are only two differences between MTT and MTS assays. For
MTT the formazan which is formed in the form of crystals needs to be dissolved by using
solubilization solution or acidified isopropanol, while in MTS there is no need of the additional
step of solubilization of formazan. Also, in MTT the absorbance is read at 570 nm while in MTS
the absorbance is read at 490 nm.
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2.4.3.1 Intrinsic cytotoxicity
For doped NPs and CPNPs, TE 71, MDA-MB-231, A549, and OVCAR3 cell lines were grown
in 96 well plates at a density 10,000 cells/well for 24 hours. Then the cells were incubated with
0.4x10-4 mg/ml, 2x10-4 mg/ml and 3.6x 10-4 mg/ml doses of respective nanoparticles in DMEM,
together with the corresponding controls (0 mg/ml and with complete media) for up to 24 hours.
Cell viability was determined 0, 24, 48, 72 and 96 hours after addition of nanoparticles by MTT
assay. For the 0 and 24 hour time point, MTT was added immediately after adding nanoparticles
and 24 hours after addition of nanoparticles, respectively. For the 48, 72 and 96 hours readings,
the nanoparticle solution was removed after 24 hours and replaced with the complete media.
MTT was then added at the corresponding time points. MTT was allowed to incubate for 4 hours
to allow formazan to form. Then the solubilization solution was added and after 6 hours the 96
well plates were read. The readings were aquired at 570nm on a Biotek ELx800 absorbance
microplate reader.
For FNPs, TE 71, MIA PaCa2, A549, and OVCAR3 cell lines were grown in 96 well plates at a
density 10,000 cells/well for 24 hours. Then the cells were incubated with 0.4x10-4 mg/ml, 2x104

mg/ml and 3.6x 10-4 mg/ml doses of FNPs in complete media together with the corresponding

controls for up to 24 hours. Cell viability was determined 0, 24, 48, 72 and 96 hours after
addition of FNPs by MTS assay. For the 0 and 24 hour time point, MTS was added immediately
after adding FNPs and 24 hours after addition of FNPs, respectively. For the 48, 72 and 96 hours
readings, the FNPs solution was removed after 24 hours and replaced with the complete media.
MTS was then added at the corresponding time points. MTS was allowed to incubate for 4 hours
to allow formazan to form. The readings were acquired at 490 nm on a Biotek ELx800
absorbance microplate reader.
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2.4.3.2 PDT
Three light doses (60 J/cm2, 120 J/cm2 and 180 J/cm2) and three nanoparticles doses (0.4x10-4
mg/ml, 2x10-4 mg/ml and 3.6x 10-4 mg/ml) along with one control dose (0 mg/ml) were used for
PDT. For each light dose four post-PDT incubation periods (0 hours, 2 hours, 4 hours and 12
hours) were evaluated. Cells were grown in 96-well plates for 24 hours. Then the cells were
incubated with different doses of doped NPs, CPNPs and FNPs. After 24 hours the media was
replaced with HBSS (Hank's Balanced Salt Solution) and the 96-well plates with the cells were
exposed to visible light by using a solar simulator (Newport 67005 Oriel Instruments) and a UV
filter (FSQ-GG400) to block the UV light. Then MTT or MTS was added to the 96-well plates
immediately after PDT (0 hours), and 2, 4 and 12 hours post-PDT incubation. The experiment
was performed 3 times (n=3). The reading was done as above (Intrinsic cytotoxicity)

2.4.4 Detection of ROS after PDT
For doped NPs and CPNPs A549 and OVCAR3 cell lines were grown in 35 mm petri dishes. 2
x10-4 mg/ml nanoparticles in DMEM were incubated with the cell lines for 24 hours. Then the
cells were washed with DPBS and were suspended in HBSS. The samples were treated with a
180 J/cm2 light dose. CellROX Green Reagent (Invitrogen) was added to the media (1)
immediately after the light treatment (0 hours) and (2) after 2 hours of post treatment incubation.
After 30 min the remaining reagent was washed away, cells were fixed with 4%
paraformaldehyde, and stained with DAPI. The cells were kept in DPBS for imaging. Three
negative controls (1) no nanoparticles and no light dose (i.e. untreated cells), (2) treatment with a
light dose of 180 J/cm2 in the absence of nanoparticles, and (3) cells incubated with nanoparticle
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dose of 2×10−4 mg/ml kept in the dark, were studied. The positive control was performed by
incubating the cells with 100 μM H2O2. For FNPs the same procedure was done by using TE 71,
MIA PaCa2, A549, and OVCAR3 cell lines and by incubating the cell lines with 2 x 10-4 mg/ml
FNPs in complete media.
2.4.5 Detection of apoptosis and necrosis by imaging
TE 71, MDA-MB-231, A549 and OVCAR3 cell lines were administered with 2 x 10-4 mg/ml
doped NPs and were exposed to the doses of light (60 J/cm2, 120 J/cm2 and 180 J/cm2). The cells
were stained with PI and annexin V FITC along with DAPI. imaging was done on these samples.
2.4.6 Endosome and lysosome tracking
OVCAR3 cell line was grown in 35 mm petri dishes. 2 x 10-4 mg/ml FNPs in complete media
was incubated with the cells. After 24 hours cells were washed with DPBS and again complete
media was added with endosome or lysosome dye. After 30 minutes the cells were washed and
stained with DAPI. The cells were suspended in HBSS for live imaging.
2.4.7 Flow cytometry
2.4.7.1 Quantification of uptake of nanoparticles
The experiment was performed for doped NPs, CPNPs and FNPs. For doped NPs and CPNPs 1 x
106 cells/ml concentration solutions of TE-71, MDA-MB-231, A549 and OVCAR3 cell lines
were incubated with 2x10-4 mg/ml nanoparticles for 24 hours. Then the cells were harvested,
washed and fixed with 4% paraformaldehyde and flow cytometry was performed on these
samples by BD Canto II flow cytometer. The data was analyzed by using FlowJo software. For
FNPs, the above procedure was done on TE-71, MIA PaCa2, A549 and OVCAR3 cell lines. As
46

the doped NPs were quenched due to presence of PCBM, the flow cytometer could not detect
their fluorescence in cells. Imaging and counting cells manually was done instead to get
quantitative measurements on uptake of doped NPs. (see ‘Imaging’ section)
2.4.7.2 Apoptosis and necrosis quantification after PDT
1 x 106 cells/ml concentration solutions of TE-71, MIA PaCa-2, A549 and OVCAR3 cell lines
incubated with 2x10-4 mg/ml FNPs for 24 hours. Then the cells were irradiated with 180 J/cm2
light dose and incubated for another 4 hours. Then the cells were harvested and stained with
annexin V-FITC and PI and kept on ice. Flow cytometry was performed on these samples by BD
Canto II flow cytometer. The data was analysed by using FlowJo software.

2.5

Imaging

Two types of imaging were done on the samples. The first includes microscopy and the second
includes the single particle spectroscopy. With microscopy images were acquired to see the
uptake of nanoparticles in cells, the detection of ROS in cells after PDT, counting of cells for
uptake quantification, and localization of nanoparticles in cells.
2.5.1 Microscopy

2.5.1.1 Confocal imaging with laser scanning spinning disc microscope
The cells administered with doped NPs and CPNPs were imaged with confocal spinning disc
microscope (Zeiss Axioskop2) with Kr-Ar ion laser. The nanoparticle fluorescence was collected
using 488 nm laser line and 488/10 band pass filter for excitation. The emission filter used was
500 LP. For DAPI, fluorescence was collected by using the DAPI filters and the mercury lamp as
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the excitation source. For CPNPs, to confirm that the CPNPs were inside the cells, confocal
images at every 0.3 µm were acquired. A selection of these slices was used representing a
spacing of the slices by 1.5 µm.
2.5.1.2 Epiluminescence imaging
Imaging was completed with an Olympus IX71 microscope using a 60X objective and Andor
Zyla sCMOS (DG-152V-C1E-FI) camera. The selection of filters was done by looking at the
emission and absorption spectra of the nanoparticles and the dyes that are used to stain the cells
for different experiments. These are explained in the subsections below. Counting the cells for
uptake quantification was completed by imaging the cells using 20X objective.
2.5.1.2.1 FNPs uptake
The fixed cells were imaged by epiluminescence microscope (Olympus IX 51) by using 60x
objective and mercury lamp for fluorescence and FITC filters (excitation filter: 491/10, dichroic
mirror: 510 DCLP, emission filter: 514 REF) to detect the fluorescence from FNPs and DAPI
filters (excitation filter: 350/52, dichroic mirror: 405 LP, emission filter: 450/20) to detect
fluorescence from DAPI stained to nucleus. Phase contrast images were acquired using halogen
lamp. The nanoparticle images and DAPI images were overlaid using ImageJ (NIH) software.
The filters were selected by observing the absorbance and emission spectra of the nanoparticles
and dyes as shown in Figure 2.3. The filters used for detection of nanoparticle fluorescence and
DAPI fluorescence separate out the fluorescence emission in different channels which then can
be overlaid to make a complete image.

48

Normalized values (a.u.)

MEH-PPV absorbance
MEH-PPV emission
DCLP 510 Dichroic mirror
514 REF Emission filter
491/10 Excitation filter

300

400

500

600

700

Wavelength (nm)

.
Figure 2.3 Filter selection based on absorbance and emission of nanoparticles and dyes used to
stain the cells.

2.5.1.2.2 Detection of ROS
The fixed cells were imaged by epiluminescence microscope (Olympus IX 51) by using 60x
objective and mercury lamp for fluorescence. For CellRox Green Reagent fluorescence the filters
were used as: excitation filter- 491/10, dichroic filter- 510 DCLP and emission filter- 525/50. For
CellRox Green Reagent fluorescence the filters were used as: excitation filter- 491/10, dichroic
filter- 510 DCLP and emission filter- 525/50 To detect the DAPI fluorescence: excitation filter350/52, dichroic mirror- 405 LP, emission filter- 450/20). To detect fluorescence of FNPs:
excitation filter-488/10, dichroic mirror-510 DCLP and emission filter-600LP were used. Phase
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contrast images were collected using halogen lamp. The images were overlaid using ImageJ
software. The filter selection was done as shown in Figure 2.4.
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Figure 2.4 Filter selection for fluorescence imaging of CellROX Green Reagent and FNPs.

2.5.1.2.3 Qdot-dopamine probe
Cells fixed after administering the Qdot-dopamine probe, were imaged by (Olympus IX 51) by
using 60x objective and mercury lamp for fluorescence. The filters used for Qdot fluorescence
were: excitation filter-350/52, dichroic mirror- 405 LP and emission filter- 400 LP. Phase
contrast images were collected using halogen lamp. Images were overlaid in ImageJ (NIH).
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2.5.1.2.4 Endosome and lysosome trackers
The cells were imaged live after staining with early endosome dye and DAPI. Imaging was done
by Olympus IX 51 microscope by using 60x objective and mercury lamp for fluorescence.
Endosome fluorescence was collected by using a set of filters as: excitation filter-491/10,
dichroic mirror- 510 DCLP and emission filter- 525/20. For FNPs the filters used were:
excitation filter-535/30, dichroic mirror- z514rdc and emission filter- 600 LP. For DAPI:
excitation filter-350/52, dichroic mirror- 405 LP and emission filter- 450/20 were used. The
same filters were used when cells were stained with lysotracker dye (Figure 2.5).
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Figure 2.5 Filter selection for imaging lysotracker or endotracker dye in cells.
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2.5.1.3 DIC confocal imaging for Qdots
Confocal images were acquired using an Olympus IX 51 upright microscope with 100X oil
immersion objective using 405 nm laser (Olympus FV5-LDPSU) for excitation. Fluorescence of
the probe was collected by Olympus FV5-ZM camera using Olympus fluoview version 4.3 FV
300 software. Sample of 6.3 µm thickness was scanned with 0.3 µm step size and 21 slices.
Fluorescence images were collected by emission filter 510LP and 505 DM. Images were
processed in ImageJ (NIH) software.

2.5.2 Single particle spectroscopy

Single particle fluorescence images and spectra were collected by using a home-built sample
scanning confocal microscope. Either the 488 nm laser line from an Ar ion laser or the 375 nm
diode laser (PicoQuant GmbH, LDH-P-C-375) in combination with a 375/10 excitation filter was
used as the excitation source depending on the sample. The laser was focused using a Zeiss 100x
Fluar objective lens (NA 1.3, WD 0.17 mm). The sample was raster scanned across the focused
laser beam using a Mad City Labs piezoelectric stage (Nano-LP100) to obtain a fluorescence
image of the sample. The fluorescence was detected by an avalanche photodiode (PerkinElmer
SPCM-AQR-14). Fluorescence spectra were obtained by a spectrograph (Pl Acton SP-2156)
with the grating (150 g/mm blaze: 500 nm) centered at 600 nm which was coupled to a
thermoelectrically cooled electron multiplying charge coupled device (EM-CCD. Andor iXon
EM+ DU-897 BI). Each fluorescence spectrum was collected with 10 seconds exposure time for
3 consecutive frames and then averaged. Each spectrum shown in the manuscript is an average
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built from 50-100 spectra, which were averaged into “ensemble spectra” in Matlab (Mathworks,
Inc., Natick, Massachusetts).
2.5.2.1 Intracellular spectroscopy in A549 with CPNPs
With the above set up A549 cells administered with CPNPs were imaged using 488 nm line from
Ar ion laser. 1 W/cm2 laser light was used. The setup included 488 nm interference filter as the
excitation filter, 495 LP dichroic mirror, and 488 REF as the emission filter.
2.5.2.2 Intracellular spectroscopy in A549 and OVACR3 with Qdots
A549 and OVCAR3 cells administered with Qdot probe were imaged with 375 nm diode laser.
The setup included 375 nm interference filter as the excitation filter, 375 nm dichroic mirror. For
collecting emission to acquire images from cell body (autofluorescence) 480/30 band pass filter
was used, while for Qdot emission 585/20 band pass filter was used. The images were then
overlaid in imageJ (NIH). The spectra were collected with 400 LP filter.
For the MMCNPs, MDA-MB-231 cells were imaged using 375 nm diode laser as the excitation
source, 375 nm interference filter for excitation filter, 375 nm dichroic mirror and 400 LP for
collecting emission to aquires images and spectra.
2.5.2.3 SPS on Qdot probe
For study of restoration of OFF probe by extracellular GSH at particle level each sample was
drop casted on glass slide and vacuum dried for 10 minutes. The samples used were OFF probe,
ON probe (after GSH addition) and bare Qdots. 6 µl of diluted sample was placed on a clean
cover slip and vacuum dried. 375 nm diode laser was used as the excitation source. Dichroic
mirror used was 375 nm. Fluorescence was collected by 400 LP.
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COMPOSITE CONJUGATED POLYMER/FULLERENE
CHAPTER 3
NANOPARTICLES AS SENSITIZERS IN PHOTODYNAMIC THERAPY
FOR CANCER

3.1

Introduction

Innovative and groundbreaking techniques have been developed to treat cancer, ranging from
surgical removal of cancer cells [13-17] to radiation therapy [5, 6] to chemotherapy with
anticancer agents [7-10]. Unfortunately, the multitude of factors and forms in which cancer
appears introduces major challenges in the development of treatment strategies. Issues such as
drug resistance and lack of site specificity require new treatment methods to be designed and
investigated that avoid such issues. By combining our current understanding of cancer
development and function with nanotechnology, new platforms that address these issues can be
envisioned and developed.
Recent studies on the development of human cancer have identified reactive oxygen species
(ROS) as playing a major role in promoting carcinogenesis for a broad variety of cancer cells
[129-132]. These ROS are also essential participants for normal functioning of cells such as in
cell signaling and apoptosis but appear at moderate levels. If formed in excessive amount ROS
can damage normal cells oxidatively leading to cell death [129, 130, 133-135]. Normal cells
contain protective mechanisms to control ROS levels thereby providing resistance to senescence
and ROS mediated apoptosis. In contrast, in cancer cells that protection is removed to allow for
elevation of ROS since cancers require elevated ROS for uncontrolled proliferation. This also
makes cancer cells more susceptible to ROS induced apoptosis by additional oxidative stress
caused by external stimuli [136-138]. This double edged sword for human cancer growth and
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proliferation opens an avenue to selectively target and eliminate cancer cells and tumors that
exhibit high levels of ROS.
A number of approaches have been investigated to introduce additional ROS in cancer cells as a
form of cancer treatment, in particular through photodynamic therapy (PDT). In PDT the level of
ROS in cells is increased by administering a photosensitizer that absorbs light [139-141]. The
excited state photosensitizer then relaxes back to the ground state by transfer of a charge or
energy to the PDT agent. In Type I reactions free radicals are directly formed or superoxide
anions are formed through oxygen [142]. Type II reactions generate singlet oxygen (1O2) by
energy transfer from the triplet excited state of the photosensitizer to the ground state of oxygen
(3O2), which in turn can form ROS [75, 76, 100, 141, 142].
While PDT has shown great promise, a major drawback that remains is the non-specific
distribution of the PDT photosensitizers, which may cause damage to healthy tissue and requires
patients to avoid exposure to light for periods of time [143, 144]. Nanobiophotonics approaches
for PDT based on new nanoparticle (NP) designs have brought significant advances to address
these issues. In this approach, the photosensitizer is delivered by conjugating it with a
nanoparticle or doping nanoparticles with the photosensitizer [100, 139, 144, 145]. Given the
promising potential due to for instance multimodality and targeted intracellular delivery that
could result in increased effectiveness and site specificity of treatment, tremendous research
effort has been dedicated to this field of research [146-149]. Quantum dots and other inorganic
nanoparticles have been reported [97, 111, 112, 114]. Magnetic nanoparticles conjugated with
photosensitizers have been investigated as well [98, 99, 150, 151]. Huang et al. have developed
silica coated gold nanoclusters to deliver Ce6 (Chlorine-6) photosensitizer into MDA-MB-435

55

cells with promising results [152]. Photosensitizer doped silica nanoparticles were prepared
though different approaches and studied for PDT application [100, 101, 103].
Soft nanoparticles have recently received attention as well. Virus capsids have been used to
deliver the photosensitizer in the cells for PDT [153]. Chitosan nanoparticles were developed to
treat skin cancer by combining PDT and electrochemotherapy [154]. Conjugated polymer
nanoparticles doped with photosensitizers for PDT were reported first by Grimland et al. [155].
In this scheme the conjugated polymer absorbs visible light, or can be excited by two-photon
excitation (2PE), at which point the excited state conjugated polymer transfers its energy to the
PDT sensitizer. This is a promising design since excitation can occur with visible or nearinfrared light either directly or by 2PE [156], and potential issues with intrinsic cytotoxicity can
be avoided provided the host polymer is biocompatible. De Gao et al. demonstrated that dye
doped polymer nanoparticles circumvent the intrinsic cytotoxicity of a PDT dye by using a
biocompatible host polymer matrix [157].
In this article we report the fabrication of composite conjugated polymer (poly[2-methoxy-5-(2ethylhexyl-oxy)-p-phenylenevinylene], MEH-PPV, (Figure 3.1A) nanoparticles doped with the
fullerene phenyl-C61-butyric acid methyl ester (PCBM), (Figure 3.1B) for PDT application. In
this study the conjugated polymer MEH-PPV was used as the host polymer for its high
extinction coefficient and well-known efficient charge and energy transfer properties to PCBM
[158]. The doping level was set at 50 wt% PCBM, which is ideal for efficient charge transfer
between conjugated polymers and fullerenes since the quantum efficiency approaches 1 [159].
Fullerene has been successfully used for PDT applications in molecular and aggregated
nanoparticle form [160-165]. However, there are severe intrinsic cytotoxicity issues associated
with fullerenes [164]. Here we show that the composite MEH-PPV/PCBM nanoparticles are not
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intrinsically cytotoxic even though fullerene is present, show specificity towards cancer cells,
yield highly effective PDT treatment at low light doses, and are able to induce apoptosis in
human ovarian cancer (OVCAR3) in-vitro.

3.2

Results and Discussion
3.2.1

Nanoparticle fabrication and characterization
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Figure 3.1 A) Chemical structure of MEH-PPV, B) chemical structure of PCBM, and C)
absorption and emission spectra of composite MEH-PPV/PCBM NPs in water
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Figure 3.2 TEM image of 50 wt% PCBM doped MEH-PPV NPs showing the size of NPs.

The polymer-fullerene composite nanoparticles were fabricated by the reprecipitation method as
reported previously [127]. NP size was characterized by DLS and an average size of 61.5±23.3
nm was found. The TEM image shown in Figure 3.2 confirmed the size of the doped NPs. The
zeta potential of these NPs was measured to be -9.66±8.12 mV implying a neutral to slightly
negatively charged surface. This neutral to slightly negatively charged surface state may play a
role in the observed specificity of the NPs to cancer cells (vide infra) since positive surface
charge leads to preferential uptake by many normal cell lines [166-168]. The size range we can
obtain with these NPs (~20-100 nm) [127] is ideal for internalization [169-171]. Figure 3.1 C
shows the absorption and emission spectra of NPs in water. The absorption maximum is located
at 498 nm. MEH-PPV is intrinsically fluorescent and the emission maximum is located at 586
nm for MEH-PPV in NPs. However, the emission from blended NPs is quenched due to the
charge transfer from MEH-PPV to PCBM [127, 158, 172]. The fluorescence emitted by the NPs
is still easily detected with sensitive detectors due to the dynamic nature of the quenching
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process and the large number of available chromophores [172, 173], but may limit general
applicability for e.g. in-vivo tracking.

3.2.2

Evaluation of nanoparticle uptake

The extent of uptake of the NPs was determined by confocal fluorescence imaging. Fluorescence
and corresponding phase images are shown in Figure 3.3. Although the NPs are quenched (vide
supra), the fluorescence from NPs can be seen in the OVCAR3 cell line, and to a lesser extent in
A549 and MDA-MB-231 cell line. There is no detectable fluorescence of NPs observed in the
TE-71 cell line. These data suggest that the TE-71cell line either uptakes a very low amount of
NPs or no NPs at all, while the cancer cell lines take up significant amounts of NPs. This
apparent selectivity in uptake between normal and cancer cell lines can be explained on the basis
of surface charge on the NPs and on the cell membrane, and differences in metabolic rate or
aggressiveness between the normal cells and cancer cells.
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TE-71

MDA-MB-231
A549
OVCAR3
2X10-4mg/ml 50 wt% PCBM doped MEHPPV NPs
Figure 3.3 Confocal fluorescence images and corresponding phase contrast images of TE-71,
MDA-MB-231, A549, and OVCAR3 incubated with 2x10-4 mg/ml composite MEH-PPV/PCBM
NPs for 24 hours in dark. NP uptake increases in the order TE-71 < MDA-MB-231 < A549 <
OVCAR3. The phase contrast images show that the morphology of the cells is not affected by
the presence of NPs

The NPs exhibit a zeta potential of -9.66±8.1mV and so are neutral to slightly negatively
charged. It has been shown that cancer cells have less negative charge on their surfaces as
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compared to normal cells [174], which allows NPs to have more interaction with cancer cells
than with the normal cells. The higher metabolic rate of cancer cells also favors higher uptake of
NPs compared to normal cells [131, 175-177]. Quantification of nanoparticle uptake was not
successful by flow cytometry due to weak nanoparticle fluorescence (Figure 3.4)

TE-71

A

B

C

D

Figure 3.4 Flow cytometry for quantitative uptake of NPs in A) TE-71, B) MDA-MB-231, C)
A549 and D) OVCAR3. Due to the quenched NPs the fluorescence of NPs was not detectable by
flow cytometer

61

A Total cell population

OVCAR3

A549

MDA-MB-231

TE-71

Cell with NPs
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Figure 3.5 Quantification of NPs uptake by different cell lines by cell counting in images. A) left
column is images of DAPI channel for total cells counted and right column is NPs fluorescence
channel for cells with NPs, B) bar graph for showing % cell population having NPs.
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The quantitative measurements on uptake of NPs by different cell lines were completed by cell
counting by imaging instead. Figure 3.5 shows the representative images for each cell line. The
total number of cells counted was calculated my counting the nuclei stained by DAPI. The
number of cells which have NPs was decided by counting the fluorescence of NPs in cells. At
least 4 number of fields were taken for counting the cells. The total number of cells for each cell
line was above 500. The number of 1) total cells counted, 2) cells with NPs, 3) % cells with NPs
and 4) fields of view are summarized in
Table 3.1
Table 3.1 Number of total cells counted, cells with NPs, fields of view and % cells with NPs.
Cell line

TE-71

MDA-MB-231

A549

OVCAR3

Total cells

715

646

1035

1063

Cells with NPs

6

85

944

913

Field of view

5

6

4

6

% cells with NPs

0.8

13

91

85

Among the cancer cell lines differences in uptake are also observed, which is attributed to
differences in the aggressiveness of the cancer cell lines. With increase in metabolic rate of the
cell line, the uptake of NPs is also expected to increase. It is well known that the OVCAR3 cell
line is more aggressive than MDA-MB-231 or A549 [176, 178]. We also considered that the
uptake mechanism could play a role in the variation of uptake of NPs by different cancer cell
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lines. It is well known that the uptake of nanoparticles of size up to 200 nm is mainly by clathrinand claveolae-mediated endocytosis, and by pinocytosis or macropinocytosis [111]. Positively
charged NPs are uptaken by all the three of these endocytic pathways while negatively charged
NPs are uptaken only by clathrin and caveolae-mediated pathways and not by pinocytosis [111].
Specifically, it has been shown that for A549 NPs are uptaken only by clathrin-mediated
endocytosis [65] while for OVCAR3 NPs go through an energy dependent uptake pathway
[179], which can be any or all of the three pathways discussed above. From these reports it can
be speculated that the high uptake by OVCAR3 is due to the involvement of clathrin- and
caveolae-mediated endocytosis, and macropinocytosis. In contrast, for A549 and MDA-MB-231
NP uptake proceeds only by clathrin or caveolae mediated endocytosis, which may result in
lower amounts of NP uptake.

3.2.3

Evaluation of intrinsic nanoparticle cytotoxicity

Intrinsic cytotoxicity of the NPs was first evaluated qualitatively by confocal imaging. The phase
contrast images in each panel in Figure 3.3 show that the morphology of the cells is not changed
after uptake of NPs. The in-vitro cytotoxicity of these NPs was subsequently determined
quantitatively by cell viability MTT assays. The MTT assays were completed by administering
three doses of NPs to each of the four cell lines and evaluating the relative proliferation for 96
hours in comparison with the untreated cell lines as control (0 mg/ml NPs dose for each cell
line). It can be seen from Figure 3.6 that at the lowest dose of NPs all the cell lines have cell
viability that is near 100%. At 2x10-4 mg/ml there is minor cell death immediately upon adding
NPs. However, the cell population regrows normally afterwards. For the MDA-MB-231 cell line
the maximum tolerable dose is between 2x10-4 and 3.6x10-4 mg/ml.
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Figure 3.6 Results of MTT viability assays completed for cells incubated with NPs in dark.
Three NP doses and a control were evaluated for each cell line (A) TE-71, B) MDA-MB-231, C)
A549, and D) OVCAR3). Incubation times in dark of 0, 24, 48, 72, and 96 hours were
considered.
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At 3.6x10-4 mg/ml the viability of this cell line is 0, which suggests that at this concentration the
NPs are cytotoxic to the MDA-MB-231 cell line while for the other cell lines considered here no
cytotoxicity is observed. Thus, the MDA-MB-231 cell line appears to be unusually sensitive to
the presence of the composite NPs compared to the other cancer cell lines. Since the normal
control is unaffected it can be suggested that the composite NPs have anticancer properties
specific to the MDA-MB-231 cell line at the 3.6x10-4 mg/ml dose that may merit further study.
The normal proliferation of the cell lines in presence of NPs when kept in dark can also be
plotted in a way shown in Figure 3.7. The cells can be seen to proliferate normally upto 96 hours.

Proliferation of cell lines in presence of NPs
8
7

Normalized cell viability

6
5

0 hrs
4

24 hrs
48 hrs

3
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2
1
0

TE-71

MDA
A549
0mg/ml

OVCA

TE-71

MDA
A549
0.4mg/ml

OVCA

TE-71

MDA
A549
2mg/ml

OVCA

TE-71

MDA
A549
3.6mg/ml

OVCA

Dose of NPs (10-4)

In Dark

Figure 3.7 Proliferation of cell lines in presence of different doses of NPs as compared to control
dose (0 mg/ml) upto 96 hours. MDA-MB-231 cell line is eradicated at highest dose of NPs.

3.2.4
3.2.4.1

Composite conjugated polymer/PCBM nanoparticle photodynamic therapy
Quantitative evaluation

Effectiveness of PDT based on the composite conjugated polymer/PCBM NPs was quantified by
MTT assays. Each of the four cell lines was incubated with three different doses of NPs. Each
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sample type (12 total) was treated with three different doses of light (36 data points). In addition,
the experiments described above were completed in four replicates so that after each period of
irradiation with light, samples could be tracked for four different incubation times (i.e.
incubation in dark after irradiation). The latter experiment was completed to determine the time
frame for treatment to be effective, since once elevated ROS levels are generated through PDT,
these levels will not dissipate instantaneously after PDT has been completed. Controls were
completed in the absence of NPs (36 data points). An additional control experiment was
completed to prove the formation of ROS upon PDT. The presence of ROS was confirmed
immediately after PDT and after post-PDT dark incubation (2 hours) with CellROX Green
Reagent, as shown in Figure 3.8. These data support that photo-induced cell death are related to
an ROS mechanism. Figure 3.9 shows the data obtained from MTT assays. The panels A, B, C
and D in Figure 3.9 show the cell viabilities for the samples collected after post-PDT incubation
times (in dark) of zero hours (i.e. immediately following PDT), and after post-PDT incubation
times of 2, 4 and 12 hours. In each panel the cell viabilities at three doses of NPs and three doses
of light are shown together with the controls (no NPs). Data are represented with respect to the
corresponding controls, which are assumed as 100% viable. Immediately following PDT (zero
hours post-PDT incubation in dark), the viability for the TE-71 control cell line decreases at most
20%, cell viability for MDA-MB-231 also decreases up to 20%, for A549 a decrease up to 30%
is observed, and for OVCAR3 a decrease in cell viability up to 70% is observed. Phototoxicity
controls (vide infra) show no cell death upon light exposure, so up to 20% decrease in cell
viability for TE-71 suggests that a small amount of NPs were taken up. After 4 hours post-PDT
incubation in dark the data remain unchanged for TE-71, MDA-MB-231 shows an additional 5%
decrease, effectiveness for A549 doubled (from up to 30% to up to 60% cell death), and for
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OVCAR3 near complete (95-100%) cell death is observed for the 2x10-4 mg/ml and 3.6x10-4
mg/ml NP doses at light doses > 60 J/cm2.
A549

OVCAR3

A

B

C

D

E

F

Figure 3.8 Detection of ROS in A549 and OVCAR3 cells using CellROX green reagent.
Epiluminescence and phase contrast images of A) Negative control: no NPs dose and no light
dose, B) Negative control: no NPs dose, 180 J/cm2 light dose and 2 hours post-PDT incubation,
C) Negative control: 2x10-4 mg/ml NPs dose and no light dose, D) Samples with 2x10-4 mg/ml
NPs dose and 180 J/cm2 light dose with 0 hours post-PDT incubation, E) Samples with 2x10-4
mg/ml NPs dose and 180 J/cm2 light dose with 2 hours post-PDT incubation, F) Positive control
performed with 100µM H2O2
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Figure 3.9 Results for MTT cell viability assays for the TE-71, MDA-MB-231, A549, and
OVCAR3 cell lines after completion of composite MEH-PPV/PCBM based PDT. Three doses of
NPs and a control (no NPs), and three doses of light were studied. In addition, four post-PDT
incubation times,A) 0 hours, B) 2 hours, C) 4 hours, and D) 12 hours were considered
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Data for 12 hours post-PDT incubation in dark appear nearly identical to the data for 4 hours
post-PDT incubation in dark. Differences between the effectiveness of treatment between the
MDA-MB-231, OVCAR3 and A549 cancer cell lines observed in-vitro are attributed to the
difference in nanoparticle uptake between these cell lines (vide supra). These data first of all
suggest high effectiveness of the composite MEH-PPV/PCBM NP based PDT for the A549 and
OVCAR3 cell lines, while MDA-MB-231 shows only moderate effects except for the 3.6x10-4
mg/ml NP dose (already observed in dark). As discussed above (vide supra), this may suggest
that the composite NPs have anticancer properties specific to the MDA-MB-231 cell line at the
3.6x10-4 mg/ml NP dose that warrant further study. Second, composite MEH-PPV/PCBM NP
based PDT reaches its full potential for effectiveness within 4 hours. Third, the 120 J/cm2 light
dose in most instances appears to have a very similar effectiveness compared to the 180 J/cm2
light dose (which corresponds to the exposure to full direct sunlight measured at sea level, minus
UV portion of spectrum which we filtered, out experienced for 30 minutes). The 180 J/cm2 light
dose presents a practical upper limit for the light dose needed for effective composite MEHPPV/PCBM NP based PDT. Fourth, while cell viability decreases as the dosage of NPs increases
from 0.4x10-4 to 2x10-4 mg/ml, effectiveness plateaus at the 3.6x10-4 mg/ml NP dose. Thus the
2x10-4 mg/ml NP dose proved to be the most efficient dosage of NPs. Finally, the high
effectiveness of the PDT based on the composite conjugated polymer/PCBM NPs for A549 and
OVCAR3 compared to MDA-MB-231 and the control line (TE-71) indicates again the
reasonably selective uptake (especially considering no surface functionality) of the NPs by
certain cancers as discussed above.
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3.2.4.2

Live-dead imaging and qualitative evaluation

Further insight in the composite MEH-PPV/PCBM NP based PDT was gained by fluorescence
imaging using a live/dead staining scheme and phase imaging. In addition, these samples were
also stained with propidium iodide (PI) and FITC-annexin V to observe necrosis and apoptosis,
respectively. Cell lines were again treated with nanoparticles and three different light doses.
60 J/cm2

120 J/cm2

180 J/cm2

180 J/cm2(control)

OVCAR3

A549

MDA-MB-231

TE-71

0 J/cm2(control)

Figure 3.10 Live/dead stain epiluminescence imaging for observation of apoptotic (FITCannexin V, green) and necrotic cell (PI, red) death induced by composite MEH-PPV/PCBM
based PDT. Cell nuclei were stained with DAPI (blue). The cell lines TE-71, MDA-MB-231,
A549 and OVCAR3 were treated with a 2x10-4 mg/ml NP dose and underwent PDT treatment at
three light doses (columns labeled 60, 120, and 180 J/cm2). Post-PDT incubation time was 4
hours. Necrotic death is observed by the purple color of the nucleus due to mixing of red and
blue channels upon overlaying the fluorescence images. The fluorescence images are overlayed
on the corresponding phase contrast images to observe cell morphology simultaneously. Control
data are shown in the left column (no NPs, no exposure to light, i.e. normal control) and the right
column (no NPs, exposure to light, i.e. phototoxicity control)
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Based on the quantitative analysis, we settled on the 2x10-4 mg/ml NP dose for this experiment.
Two controls, cells without NPs kept in dark (dark control) and cells treated with light in the
absence of NPs (phototoxicity control), were studied as well. The data (Figure 3.10) again show
that treatment of OVCAR3 (which takes up the most nanoparticles) is the most effective. At the
120 J/cm2 light dosage apoptosis and necrosis is observed, while at the higher light dosage only
necrosis is observed. Cell morphology clearly indicates treatment induced death. Similar
observations are made for A549, but less dramatic due to the somewhat lower uptake of
nanoparticles by that cell line and only necrosis is observed. The TE-71 cell line is not affected
by treatment except at the highest light dosage when considering cell morphology. The PI and
FITC-annexin V stains give a negative result, however, and the cell morphology appears pristine
in all other cases. The same observation is made for MDA-MB-231. The control shows no
observable cell damage. The PI and FITC-annexin V stains give a negative result and the cell
morphology appears pristine for all controls.
In addition, the data clearly show that the A549 cell line only undergoes necrosis while the
OVCAR3 cell line shows apoptosis at 60 and 120 J/cm2 and necrosis at 180 J/cm2. Apoptosis is
a programmed cell death important in maintaining the growth and immune responses of the body
[180, 181]. During the genetic mutations in normal cells that lead to development of cancer, the
cell loses the ability to undergo apoptosis, which is often due to mutation of the p53 gene. This
process is responsible for tumor development by postponing the death of cancer cells. If a
treatment can induce or enhance apoptosis in cancer cells then the likelihood of successful long
term treatment increases significantly, because the potential for regrowth of cancer cells and
tumor tissue between treatment sessions becomes much smaller [180, 182, 183]. Based on the
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findings of this live/dead imaging experiment, the cancer treatment strategy discussed herein has
shown very promising in-vitro results for A549 and even more so for OVCAR3.

3.3

. Conclusion

Photodynamic therapy based on composite MEH-PPV/PCBM NP as a source of ROS has been
shown to be a highly effective treatment approach for cancer cell lines in-vitro. The all-organic
nanoparticles are not cytotoxic at doses effective for PDT, and present a treatment scheme that is
benign to normal non-cancerous cells. PDT by means of the composite MEH-PPV/PCBM NP
works under relatively low light conditions for reasonable short exposure times due to the high
absorption cross-section of the polymer nanoparticles, thus avoiding phototoxicity. It is fully
effective in a single treatment for ovarian cancer cells and about 60% effective for A549 cancer
cells 4 hours after treatment was initiated in-vitro, and already shows specificity to cancers
without surface modification. In-vitro a nanoparticle dose of 2 x 10-4 mg/ml together with a light
dose of 180 J/cm2 is already sufficient to observe these results 4 hours after treatment for A549
and MDA-MD-231. For OVCAR3 a light dose of 120 J/cm2 is sufficient, and apoptosis is
observed as a mechanism of cell death induced by PDT based on composite MEH-PPV/PCBM
NP. The latter is a promising finding for potential development of treatment for ovarian cancer
by the PDT scheme discussed herein.
Quantitative differences between the effectiveness of treatment between the MDA-MB-231,
OVCAR3 and A549 cancer cell lines observed in-vitro can be attributed mainly to the difference
in nanoparticle uptake between these cell lines. Further improvement of targeting of the
nanoparticles to cancers will be investigated in the near future.
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CHAPTER 4

4.1

CONDUCTING POLYMER NANOPARTICLES FOR PDT

Introduction

Chemotherapy [7-11], surgery [3, 4, 184] and radiotherapy [5, 6] are currently widely used in
clinical settings for treatment of cancer. Multimodal treatments such as chemotherapy combined
with immunotherapy [185, 186] or with radiotherapy [187] are also used. Research on further
treatment development is also ongoing. Surgery has recently seen improvements by the
development of laser surgery [13-17] and fluorescence imaging guided surgery[18, 188]. Small
molecules such as doxorubicin [21, 56, 189] and STAT3 inhibitors [34, 36, 190, 191] and
nanoparticle drugs [50, 192]are currently under investigation. In addition, photodynamic therapy
(PDT) has been shown to be a promising treatment scheme for cancer through clinical trials and
preliminary application at treatment centers [193-198].
In PDT a photosensitizing material is internalized by cancer cells, and subsequently these cells
are irradiated with light. The photosensitizer generates Reactive Oxygen Species (ROS) under
irradiation that can induce oxidative stress and structural damage in cancer cells, with the aim to
achieve cell death [75, 76, 82, 199, 200]. For normal cells, ROS are essential in the regulation of
cell functions such as cell signaling and apoptosis. ROS levels are kept in check under normal
circumstances by intrinsic antioxidants present in cells. Studies on formation of cancerous cells
have shown that when ROS levels increase to an extent where they can no longer be removed by
the intrinsic antioxidants present in cells, this condition can lead to cancer [129-132]. As such,
cancer cells need elevated amounts of ROS for proliferation, but at the same time cancer cells do
not have sufficient antioxidants to scavenge ROS. Thus even while cancer cells thrive with
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elevated ROS levels, they are also very susceptible to externally stimulated elevations of ROS
levels [136-138, 177].
Developments in nanotechnology inspired photosensitizers have brought new developments to
PDT. Various inorganic nanoparticle photosensitizers such as quantum dots[111, 112], gold
nanoparticles [96, 97, 113] magnetic nanoparticles [98, 99], silica nanoparticles [100-103], and
titanium oxide nanoparticles [114] have been developed and studied. A few examples of organic
nanoparticle photosensitizers such as methacrylate polymer nanoparticles doped with verteporfin
as the photosensitizers and polymeric micelles of block copolymer poly(ethylene glycol)–copoly(D,L-lactic acid) (PEG-PLA) loaded with 5,10,15,20-tetrakis(mesohydroxyphenyl)porphyrin
(mTHPP) as the photosensitizer have been reported [105, 201]. Liposomes doped with various
photosensitizers have been studied for application in PDT [106]. Aminolevulinic acid
encapsulate liposomes were recently reported for PDT application [202]. Phthalocyanine
conjugated polypropylenimine dendrimers, and porphyrine phthalocyanine decorated dendrimers
[107, 108] have also been reported.
Recently, photosensitizer-doped conducting polymer nanoparticles have received attention as
potential photosensitizers for PDT. Photosensitizer doped conjugated polymer nanoparticles
were developed and characterized by Grimland et al. Singlet oxygen formation by
tetraphenylporphyrine (TPP) photosensitizer under one- and two-photon excitation was proven
by UV-vis spectroscopy, and DNA damage as proof-of-concept was shown by these authors.
[155]. Shen et al. concurrently proved the formation of singlet oxygen for tetraphenylporphyrine
(TPP)

photosensitizer

doped

conjugated

polymer

nanoparticles

by

singlet

oxygen

luminescence[110]. Zhang et al. more recently followed a similar nanoparticle design scheme
with meta-tetra-(hydroxyphenyl)-chlorin (m-THPC) as photosensitizer to produce ROS[203].
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In this article, conducing polymer nanoparticles fabricated from the conducting polymer poly[2methoxy-5-(2-ethylhexyloxy)-1,4-phenylenevinylene] (MEH-PPV Fig. 1A) were studied for
application in PDT. Photosensitization was found to be intrinsic to these conducting polymer
nanoparticles (CPNPs) without the use of photosensitizer dopants. These CPNPS were
investigated in-vitro for their potential application in PDT for cancer treatment. The CPNPs show
bright emission in-vitro that enables fluorescence imaging of internalized CPNPs. It was
observed that these CPNPs have a strong intrinsic bias towards the cancer cell lines studied here
without surface modification. The CPNPs were observed to be not intrinsically cytotoxic (no
cytotoxicity observed in dark), and show very promising PDT results. PDT was highly effective
for lung and ovarian cancer at moderate intensities of visible light, without observation of
phototoxicity.

4.2

Results and discussion
4.2.1 CPNP fabrication and characterization

The CPNPs were prepared by the reprecipitation method [127, 128, 204]. The resulting CPNPs
are small quasi-spherical clusters of about 20 to 50 polymer chains [205]. DLS data show that
the CPNPs have an average size of 34±6 nm in diameter with a narrow size distribution (Figure
4.1 B), consistent with our previous reports [127]. The size of CPNPs was confirmed by TEM as
shown in Figure 4.2. The zeta potential of the CPNPs is -12.4 ± 3.7mV, showing that the CPNPs
surface have slight negative to no charge. The absorption and emission spectra of CPNPs
suspended in water shown in Figure 4.1 C depict a broad range of absorption in the visible
spectrum having an absorption maximum at 494 nm and an emission maximum at 591 nm,

76

respectively. The CPNPs were observed to be stable in cell culture media for 96 hrs as
previously documented by Wu et al[205]
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Figure 4.1 A) Structure of MEH-PPV polymer, B) DLS showing size of CPNPs, and C)
Absorption (red line) and emission (black line) spectra of CPNPs.

Figure 4.2 TEM image of CPNPs to show the size of the nanoparticles.
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4.2.2 In-vitro evaluation of CPNP uptake

Spherical nanoparticles of around 30 nm in diameter [169-171] and with positive zeta potential
on their surfaces are typically uptaken easily by cells [166-168, 174, 206-208]. The size range is
approximated well by the CPNPs discussed herein, while the surface charge is not ideal for
cellular uptake, the small magnitude of the negative charge on the CPNPs was observed to
actually contribute to desirable selectivity in uptake (vide infra). Figure 4.3 shows the confocal
fluorescence images and corresponding phase contrast images of the cell lines incubated with 4
doses of CPNPs (0 mg/ml, 0.4 x 10-4 mg/ml, 2 x 10-4 mg/ml and 3.6 x 10-4 mg/ml), revealing
significant CPNP uptake. It can be seen that the different cell lines take up different amounts of
CPNPs and that the uptake is dose dependent. Cancer cell lines abundantly take up nanoparticles
in comparison to the normal control cell line. The quasi-selective uptake by cancer cell lines over
the control cell line can be attributed to the charge on the surface of CPNPs (slight negative to
neutral) and on the cell membranes. It has been reported that the charge on normal cell lines is
highly negative whereas the cancer cell lines have less negative charge on them [174, 209]. Due
to lesser negative charge on the cell surface of cancer cells the CPNPs have less repulsion from
the cancer cell line surfaces as compared to the normal cell lines. Comparing the cancer cell
lines, OVCAR3 has the highest uptake followed by A549 and lastly MDA-MB-231. The high
uptake of CPNPs by OVCAR3 cells can be attributed to the aggressiveness of this cell line [135,
175, 176, 178].
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3.6 (X10-4 mg/ml)
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Figure 4.3 From top to bottom confocal fluorescence images and corresponding phase contrast
images of TE-71, MDA-MB-231, A549 and OVCAR3 cells incubated with increasing doses of
CPNPs. CPNP doses are indicated at the top of the figure and are expressed in units of 10 -4
mg/ml. Green dots represent the fluorescence from CPNPs and the blue color indicates nuclei
stained with DAPI.
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CPNP uptake efficiency was further quantified by flow cytometry. Figure 4.4 A-D shows
normalized histograms indicating the distribution of fluorescence intensity detected for cells
incubated with CPNPs. All cell lines appear to have taken up nanoparticles, although there is an
apparent difference in extent of uptake. For clarity, the flow cytometry data (fraction of
population that took up nanoparticles and detected fluorescence intensity) were replotted as bar
graphs in Figure 4.4E-F. The percent cell population that has internalized CPNPs is shown in
Figure 4.4E. The data show that 68.2% of TE-71 cells internalized CPNPs, while for MDA-MB231, A549, and OVCAR3 81.6%, 85.6%, and 90.05% of the cells internalized CPNPs. The
average fluorescence intensity of CPNPs in each cell line is shown in Figure 4.4F. The low
average fluorescence intensity observed for TE 71 implies that even though there are 68.2 %
cells which have internalized CPNPs, the amount of CPNPs in each cell is very small. The
OVCAR3 and A549 cell lines exhibit comparable average fluorescence intensity of CPNPs
followed by MDA-MB-231. The flow cytometry data thus confirm the qualitative observations
made by fluorescence imaging (Figure 4.3).
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Figure 4.4 Flow cytometry data on uptake of CPNPs by each cell line. Representative data
showing normalized cell count of A) TE 71, B) MDA-MB-231, C) A549 and D) OVCAR3 cell
lines with respect to detected CPNP fluorescence. E) Percentage of the cell population for each
cell line that has internalized CPNPs (green bars) together with controls (red bars, no CPNPs,
n=2), F) Average fluorescence intensity detected from CPNPs for each cell line depicted by
green bars, together with controls (red bars, no CPNPs, n=2)

To confirm that the CPNPs were indeed internalized as opposed to being stuck to the outside cell
membrane, 3D confocal imaging experiments were completed. CPNPs are detected in the
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intracellular environment throughout the 3D stack of images, as shown in Figure 4.5 using A549
as a representative example. Similar results were obtained for each cell line studied herein. These
images show that the CPNPs are located mostly at the periphery of the nucleus.

Figure 4.5 Confocal slices of an A549 cell with CPNPs (green dots) at the periphery of the
nucleus (blue).

The stability of the CPNPs inside the cells was evaluated by Single Particle Spectroscopy. The
A549 cell line was selected for this experiment, since it internalizes CPNPs but not to the extent
that individual particles or clusters cannot be identified. Figure 4.6A and B show the brightfield
and fluorescence image of a single A549 cell that internalized CPNPs. The expanded image in
Figure 4.6C allows for the observation of single CPNPs and clusters of CPNPs. These were
individually addressed by confocal laser and emission spectra were collected for 100
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CPNPs/CPNP clusters. The resulting single particle ensemble spectrum is shown in Figure 4.6 D.
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Figure 4.6 Single particle imaging and spectroscopy on CPNPs inside A549 cells. A) Bright field
image of an A549 cell, B) Raster-scanned fluorescence image of the corresponding A549 cell
with CPNPs inside the cell. The CPNPs can be seen clearly as spherical bright spots in the
magnified region of the image shown in panel C). D) The ensemble spectrum of CPNPs inside
the cell (black line) has max at 588nm. The spectral shape and emission maximum indicate that
the CPNPs remain stable in the intracellular environment. The inset in D) shows the
autofluorescence of the cell with max 550nm. A shoulder at this wavelength can be seen in the
spectrum of CPNPs.
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The peak emission at 588 nm is comparable to the peak emission at 591 nm observed for freshly
prepared CPNPs measured in water. Conversely, well dissolved MEH-PPV in a good solvent
emits around 553 nm [127]. These data confirm that the CPNPs are stable and intact inside the
cell.

4.2.3 Intrinsic cytotoxicity of CPNPs
The intrinsic cytotoxicity of the CPNPs was evaluated quantitatively by MTT assays. Figure 4.7
shows MTT data for the four cell lines incubated with three doses of CPNPs (0.4x10-4 mg/ml,
2x10-4 mg/ml and 3.6x10-4 mg/ml) together with the control (0 mg/ml). At no point is intrinsic
cytotoxicity of CPNPs observed. The cells proliferate normally in presence of CPNPs as
compared to the control dose. These data suggest that no ROS are formed in dark (vide infra), in
contrast to other sensitizers such as quantum dots, which even in the absence of light can still
lead to elevated ROS levels in cells, and cause damage to cell organelles or lead to cell death
[210, 211]. The data was also plotted in a way to show the normal proliferation (Figure 4.8 A).
The image shown in Figure 4.8 B shows normal functioning of the cells even when the CPNPs
are inside the cells.
As can be seen from the image, the dividing cells shown in yellow circle seem to share the
nanoparticles shown in green color. This suggest that the cells function normally without any
interference by the nanoparticles. Also, even if the cells are multiplying during the incubation
period, the sharing of nanoparticles will leave all the cells with nanoparticles in them.
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Figure 4.7 MTT viability assays to evaluate the intrinsic cytotoxicity of CPNPs. A) TE-71, B)
MDA-MB-231, C) A549 and D) OVCAR3 with control dose (0 mg/ml) and three doses of
CPNPs (0.4x10-4 mg/ml, 2x10-4 mg/ml and 3.6x10-4 mg/ml). The incubation periods are 0, 24,
48, 72 and 96 hours.
85

A

Proliferation of cell lines in presence of CPNPs

16

Normalized cell viability

14
12
10
0 hrs
8

24 hrs
48 hrs

6

72 hrs
96 hrs

4
2
0
TE-71

MDA

A549

0mg/ml

OVCA

TE-71

MDA

A549

0.4mg/ml

OVCA

TE-71

MDA

A549

2mg/ml

OVCA

TE-71

MDA

A549

3.6mg/ml

OVCA

Dose of NPs (10-4)

B

Figure 4.8 A) MTT data to show normal proliferation of different cell lines in presence of
different doses of CPNPs as compared to the control dose (0 mg/ml) upto 96 hours, B) an image
of OVCAR3 cell line administered with CPNPs. Green color is the fluorescence of CPNPs.and is
overlid o phase contrast image. Dividing cell is shown in yellow circle.
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4.2.4 PDT

Figure 4.9 shows MTT data quantifying the viability of the four studied cell lines after PDT. The
cell lines were incubated with three different doses (0.4x10-4 mg/ml, 2x10-4 mg/ml and 3.6x10-4
mg/ml) of CPNPs and then exposed to different light doses (60 J/cm2, 120 J/cm2 or 180 J/cm2).
These moderate light doses are sufficient for an effective PDT treatment, [76, 193, 212, 213],
and are possible due to the large absorption cross section of MEH-PPV used herein in the visible
spectrum (> 106 L/mol cm-1). No phototoxicity effects were observed in these studies (vide infra)
Evaluation of treatment results was completed immediately after the PDT application (Figure
4.9A), and after an incubation (waiting) period of 2 hours (Figure 4.9B), 4 hours (Figure 4.9C),
and 12 hours (Figure 4.9D). In each panel (A, B, C and D) the cell viability at three CPNP doses
and three light doses are compared with the control for each cell line (0 mg/ml CPNPs).
The cell viability in each panel decreases from TE-71 to MDA-MB-231 to A549 to OVCAR3. In
addition, for each cancer cell line, viability decreases with increasing CPNP dose, although the
highest dose (3.6x10-4 mg/ml) does not show significant improvement. For TE71 there is no
significant CPNP dose response due to the limited CPNP uptake. For A549 and OVCAR3
dependence on the light dose is also observed, where increasing light dose results in lower
viability. The 180 J/cm2 light dose still shows measurable improvement in reducing cell viability
in those cases. This observation can again be attributed to the limited CPNP uptake by TE71 and
MDA-MB-231 in comparison to A549 and OVCAR3.
.
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Figure 4.9 MTT assay to evaluate the cell viability after application of PDT. Post-PDT
incubation period A) 0 hours, B) 2 hours, C) 4 hours, and D) 12 hours. Each panel has four cell
lines, TE-71, MDA-MB-231, A549 and OVCAR3. Each cell line is administered with three
doses of CPNPs (0.4x10-4 mg/ml, 2x10-4 mg/ml and 3.6x10-4 mg/ml) and 0 mg/ml as the control
dose. The colored bars represent light doses (red: 60 J/cm2, green: 120 J/cm2, blue: 180 J/cm2).
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In contrast, the higher amount of CPNPs uptaken by cells lines such as A549 and OVCAR3 will
lead to higher amounts of ROS being generated upon irradiation, which is reflected in the
observation of low cell viability. It is, however, not possible to rule out the effects of differences
in inherent ROS levels of different cell lines on susceptibility to undergo oxidative stress through
PDT [214, 215]. Overall, effectiveness of PDT scales with the extent of CPNP uptake and
administered light dose. The 2x10-4 mg/ml dose of CPNPs under light dose of 180 J/cm2 was
found to be most effective. For the OVCAR3 cell line cell viability is near zero under these
conditions.

4.2.5 CPNPs as the source of ROS
It’s been previously shown that conducting polymers are able to charge- and energy transfer
from their triplet excited state to the ground state of oxygen to form singlet oxygen [216-218].
The rapid photobleaching of conducting polymers, both reversible and irreversible, has been
attributed to this mechanism [219]. It was therefore hypothesized that CPNPs could yield ROS
formation upon photoirradiation without the need for photosensitizer dopants. Specifically, upon
exposure to light the CPNPs are photoexcited and in the case of MEH-PPV have an
approximately 1.25% probability of intersystem crossing to the triplet excited state [220] .
Oxygen can deactivate the latter by energy transfer, which results in excitation of the oxygen
triplet ground state to the highly oxidative singlet oxygen excited state (Type II
photosensitization) [75, 76, 81, 82]. Alternatively, oxygen or other substrates such as solventand biomolecules can accept an electron from the triplet excited state to form radicals (Type I
photosensitization) [75, 76, 81, 82]. It has previously been shown that conducting polymers can
interact directly with oxygen to form superoxide in a reversible fashion [221-223].
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Figure 4.10 Epiluminescence images with corresponding phase contrast images of A549 and
OVCAR3 cell lines for detection of ROS in by CellRox green reagent. A) Control in absence of
treatment (no CPNPs, no light). B) Negative control by means of light exposure in absence
CPNPs. C) Negative control by means of incubation with CPNPs in absence of light exposure.
CPNP emission can be detected. D) Fluorescence images taken immediately after PDT, and E) 2
hours post-PDT. F) Positive control with 100µM H2O2
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If other substrates are involved, then these typically act as intermediate radicals toward the
formation of superoxide. The superoxide anion may react further to form hydrogen peroxide,
which in presence of iron forms highly reactive hydroxyl radicals [86, 131, 224, 225]. Regardless
of whether Type I or Type II photosensitization occurred, the resulting reactive oxygen then
react with biomolecules like lipids, nucleic acids etc. to form peroxides leading to a chain
reaction in the cell organelles causing damage to and potential death of the cell.
To confirm that the CPNPs are indeed the source of ROS formation in cells upon irradiation with
light, cells were stained with CellRox Green Reagent (CGR). This reagent is non-fluorescent or
very weakly fluorescent while in a reduced state and upon oxidation by ROS shows strong green
fluorescence. Formation of ROS was detected with CGR staining in A549 and OVCAR3 cell
lines that had taken up CPNPs and were exposed to light, both immediately after in-vitro PDT
(Figure 4.10D) and 2 hours after PDT was completed (Figure 4.10E). Further confirmation
comes from the control experiments with CGR staining. Figure 4.10A-C shows three negative
controls: in absence of the treatment (no particles, no light), in absence of CPNPs with 180J/cm2
light dose, and in absence of photoirradiation with 2 x 10-4 mg/ml CPNPs dose, respectively. As
CGR emission is only detected when full PDT treatment is applied, it can be concluded that the
CPNPs are the source of ROS under PDT. The data in Figure 4.10B (no particles, 180J/cm2 light
dose) suggest that under the PDT conditions used here no acute phototoxicity occurs, since no
elevated ROS levels are detected and cell morphology looks normal. In addition, the data in
Figure 4.10C (particles, no light) also support the MTT data that CPNP are not acutely cytotoxic,
since no detectable ROS response is observed in absence of light.
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4.3

Conclusion

Conducting polymer poly[2-methoxy-5-(2-ethylhexyl-oxy)-p-phenylenevinylene] (MEH-PPV)
nanoparticles (CPNPs) were studied for application in biophotonics and therapeutics, specifically
for PDT. The nanoparticles are abundantly taken up by cancer cells while exhibiting promising
specificity to cancer cells without specific targeting of surface receptors. Cells proliferate
normally in the presence of CPNPs, indicating the absence of intrinsic cytotoxicity. The bright
intrinsic fluorescence of the CPNPs is attractive for localization after administering the CPNPs,
while the large absorption cross section allows the use of low to moderate light levels for ROS
generation. It was observed that the effectiveness of PDT scales with the extent of CPNP uptake
and administered light dose. The 2x10-4 mg/ml dose of CPNPs under light dose of 180 J/cm2 was
found to be the most effective treatment scheme in-vitro. Promisingly, for the OVCAR3 cell line
cell viability is near zero under these conditions.
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FOLIC ACID CONJUGATED CONDUCTING POLYMER
CHAPTER 5
NANOPARTICLES FOR TARGETED PHOTODYNAMIC THERAPY
5.1

Introduction

In the last two decades a steady decrease in cancer patient mortality has been achieved due to
intensive research and improvements in treatments [226]. However, for high mortality cancers
such as pancreatic, liver, lung etc. no significant progress has been made [2]. Therefore, a
multitude of treatment schemes are still being investigated to address existing needs in cancer
therapeutics. Photodynamic Therapy (PDT) is receiving increasing attention among researchers
due to its ease of application and promising clinical results [193, 197].
In PDT a photosensitizer is administered to tissue and irradiated with visible light matching to
the absorption spectrum of the photosensitizer [76, 192]. This brings the photosensitizer into its
singlet excited state, which can then relax to the ground state through different pathways. Decay
of the excited state by fluorescence makes it possible to use some sensitizers as a tool to locate
diseased tissue, but only if the photosensitizer is targeted to that tissue. A fraction of the singlet
excited state of the photosensitizer will intersystem cross to its long lived triplet excited state.
The triplet state leads to the formation of Reactive Oxygen Species (ROS), highly reactive forms
of oxygen, which are harmful to cells and can result in cell mortality [75, 78, 79]. The
mechanism by which the triplet state of the photosensitizer leads to formation of ROS involves
two types of photooxidative pathways. In type I photooxidation charge transfer from the triplet
state of the photosensitizer to molecular oxygen yields the reactive superoxide radical ion.
Alternatively, this process can proceed with biomolecules and solvent molecules in the cells as
the acceptors to form radicals. In type II photooxidation the triplet state of the photosensitizer
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transfers energy to the triplet ground state of oxygen to form singlet oxygen [75, 76, 81, 82]. The
resulting elevated levels of ROS induce oxidative stress and cell death [75, 76, 81, 227, 228].
When a non-targeted photosensitizer is administered into the body, the patient has to be kept
away from sunlight in order to avoid toxic side effects. Photosensitizers such as verteporfin, 5aminolevulinic acid, and photofrin cause skin diseases that manifest themselves by pigmentation,
and phototoxic reactions which cause itching and burning sensation, swelling and erythema [125,
126]. To address such side effects, the photosensitizer must be targeted towards the malignant
tissue only. Nanoparticle technology has shown promise to improve the efficacy and
selectiveness of sensitizer delivery towards malignant tissue, causing less side effects. During the
last decade, monoclonal antibodies (MAbs) have been used to target cancers for diagnosis and
treatment [229]. In photoimmunotherapy (PIT), MAbs were conjugated with photosensitizers
such as haematoporphyrin derivative (HpD), chlorin e6 and phthalocyanines to achieve selective
delivery of the photosensitizer in tumors [229]. However, the current issue with PIT is optimal
control over the conjugate preparation without changing the biological properties of the
monoclonal antibodies [229]. Besides targeting cancers through specific antibody/antigen
interactions, cancer cells can also be targeted by means of the well-documented overexpression
of receptors such as folate receptors (FR) [176, 230], epidermal growth factor receptors (EGFR)
[231], Her-2 receptors [232, 233] and others depending on the type of cancer. Ligands specific
towards these receptors such as folic acid (FA), antibodies Erbitux or Cetuximab, and affibody,
respectively, can be used for enhanced selectivity of delivery. Research has been reported on
targeting ovarian cancer with different ligands to make PDT more specific. Recently PDT using
Fe3O4/Au NPs decorated with 5,10,15,20-tetrakis(4-hydroxyphenyl)-21H,23H-porphine (tHPP)
as a photosensitizer and affibody for Her-2 specificity to target SK-OV-3 ovarian cancer cells
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was studied [234]. These NPs were evaluated in xenografted tumor and were found to be very
effective in showing specificity and inhibition of tumor growth. EGFR targeted PDT using
liposomes functionalized with Cetuximab as the targeting antibody and benzoporphyrine
derivative (BPD) as photosensitizer yielded very promising results when applied to ovarian
cancer cells [116]. Research on the use of folic acid as a ligand for selective delivery of
photosensitizer in different types of cancer tissues is also well-documented and is still in
progress.

Polymeric

micelles

conjugated

with

folic

acid

to

deliver

meta-tetra

(hydroxyphenyl)chlorin (mTHPC) in KB cells in-vitro and corresponding xenografts were
studied by Syu et al.[117]. CdTe quantum dots acting as a photosensitizer and conjugated with
folic acid showed specificity to folate receptor (FR) overexpressing KB cells [118]. Similarly,
zinc tetraaminophthalocyanine (ZnaPc) conjugated with folic acid showed selective delivery of
the photosensitizer to FR positive (FR+) KB cells [119]. Graphene oxide nanoparticles loaded
with photosensitizer chlorin e6 (Ce6) and conjugated with folic acid recently showed promise
when studied in-vitro with MGC803 cells [120].
Photosensitizers that are currently applied in PDT have moderate extinction coefficients and
have high singlet oxygen quantum yield, which has provided promising result for PDT treatment
in clinical settings [235, 236]. Though a lot of work has been completed to improve the
properties of photosensitizers to make PDT an effective treatment for cancer with only minor to
no side effects, there still remain a few problems that need to be addressed. These include 1) lack
of specificity, which leads to side effects such as damage to healthy tissue and prolonged
photosensitivity of the patient, 2) hydrophobicity of sensitizer molecules that leads to
aggregation and thus reduced bioavailability and efficacy of the photosensitizer, and 3) dark
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toxicity of the photosensitizers, which could limit applicability of the photosensitizer, especially
if non-targeted sensitizers.
Photosensitizer doped conjugated polymer nanoparticles have recently received attention as next
generation photosensitizers in PDT. Grimland et al. have recently studied conducting polymer
nanoparticles acting as nanocarriers encapsulating the photosensitizer tetraphenylporphyrine
(TPP) [109]. The investigators showed formation of singlet oxygen by UV-vis spectroscopy after
photoactivating the nanoparticles by one and two photon excitation. As a proof-of-concept DNA
damage was shown in presence of these nanoparticles. Shen et al. also proved the generation of
singlet oxygen by tetraphenylporphyrine (TPP) doped in conjugated polymer nanoparticles by
photoluminescence of singlet oxygen by fluorescence spectroscopy [156]. Similarly, Zhang et al.
used meta-tetra-(hydroxyphenyl)-chlorin (m-THPC) as the photosensitizer in conjugated
polymer nanoparticles to form ROS [203].
In this article, blended poly[2-methoxy-5-(2-ethylhexyl-oxy)-p-phenylenevinylene] (MEHPPV)/Polystyrene Graft Ethylene Oxide functionalized with carboxylic acid (PS-PEG-COOH)
nanoparticles conjugated with folic acid (FNPs) were studied in-vitro for use in PDT as next
generation photosensitizers with targeted delivery. The nanoparticles were fabricated by selfaggregation of the polymer; the only chemistry that was applied was to conjugate folic acid to
the nanoparticles. The FNPs are not cytotoxic in dark, and are highly effective at producing ROS
under illumination due to the large extinction coefficient of MEH-PPV (> 107 L mol-1 cm-1). The
combination of the hydrophobicity of MEH-PPV, large negative zeta potential of the
nanoparticles, and receptor mediated uptake resulted in complete selectivity of FNP uptake by
cancer cell lines that overexpress folate receptors (FR). Among the cancer cell lines studied MIA
PaCa2 (pancreatic cancer cell line, no FR overexpression) does not show detectable uptake of
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FNPs, A549 (lung cancer cell line, minor FR overexpression) shows minor FNP uptake, and
OVCAR3 (ovarian cancer cell line, major FR overexpression) shows abundant FNP uptake. PDT
results quantified by MTS assay and confirmed by flow cytometry scale with the observed FNP
uptake as expected. These results indicate the promising nature of this photosensitizer system
due to its lack of dark toxicity, inclusion of PEG for enhanced circulation times, high rate of
ROS generation, high cell mortality for the cancer cell line that abundantly overexpresses the
targeted receptor (OVCAR3), while no cell mortality is observed for non-targeted (TE71 normal
control and MIA PaCa2) or marginally receptor overexpressing cell lines (A549), and bright
fluorescence that together with the high degree of selectivity can be used to localize the targeted
tissue.
5.2

Results and discussion
5.2.1 Fabrication, functionalization and characterization of NPs

5.2.1.1

Fabrication of FNPs

The nanoparticles (NPs) to be functionalized were fabricated by the reprecipitation method,
following a modified procedure from the one published by Wu et al.[237]. In short, a solution of
2:1 molar ratio of fluorescent hydrophobic polymer MEH-PPV and non-fluorescent comb-like
amphiphilic polymer PS-PEG-COOH in THF was quickly injected into DI water under vigorous
stirring. Due to their hydrophobicity, the MEH-PPV polymer chains and the polystyrene
backbone of PS-PEG-COOH polymer aggregate to form MPNP suspension in water. The
hydrophilic PEG and COOH parts of the non-fluorescent polymer extend towards water making
the carboxylic acid groups available on the surface of the MPNPs for further modifications. The
carboxylic acid groups were then allowed for attachment of ligands to the MPNPs. Scheme 5.1
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shows the complete process of MPNP fabrication and functionalization by conjugation of folic
acid to the COOH groups.

Scheme 5.1 Functionalization of MPNPs with folic acid by EDC reaction. 1) Formation of
MPNPS from mixed solution of MEH-PPV and PS-PEG-COOH in THF, 2) Addition of EDC to
activate the carboxyl OH groups, forming the O-Acylisourea group on MPNPs, 3) Conjugation
of folic acid to MPNPs through the formation of an amide bond.
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After MPNP fabrication NHS and EDC was added to the MPNPs suspension (Scheme 5.1, step
2) in order to activate the hydroxyl groups of COOH on the MPNPs surface by forming the OAcylisourea product, which is a better leaving group. Upon addition of 1:1 molar ratio of folic
acid to PS-PEG-COOH to the O-Acylisourea product, folic acid conjugates to the MPNPs by
formation of an amide bond between the amine of folic acid and the carbonyl group of MPNPs
while replacing the isourea group (Scheme 5.1, step 3). Unreacted folic acid was removed by
centrifugal filtration. The filtered solution is a suspension of the functionalized NPs (FNPs) in
water.
5.2.1.2 Characterization by FTIR
Formation of an amide bond between the carbonyl of MPNPs and amine of folic acid was
confirmed by FTIR. Figure 5.1A shows the FTIR spectra of MPNPs, FNPs and MEH-PPV NPs.
Figure 5.1B has the same spectra enlarged from 1000 to 2000 cm-1. There are no major
differences between the spectra of MPNPs and MEH-PPV NPs suggesting that there is no
chemical bond formation when PS-PEG-COOH and MEH-PPV polymers were mixed with each
other to fabricate MPNPs. Three particular amide bands in the FTIR spectrum of FNPs (blue
line), (1) amide I - C=O stretch at 1620 cm-1, (2) amide II – NH bend at 1580 cm-1, and (3) amide
III – 1312 cm-1,confirm that the expected amide bond was formed. There is one primary amine
(pterine ring) and one secondary amine (p-aminobenzoate moity) in folic acid (Scheme 5.1)
which can form amide bond with the carbonyl on MPNPs [238, 239]. Chen et al. have recently
showed that even though the pterine moity in folic acid is essential for the binding affinity to
folate receptors, they have observed extensive interactions between glutamate group in folic acid
and side chains of the proteins lining the groove of folate receptors through six hydrogen bonds
and some backbone interactions [240]. Thus even if the primary amine in the pterine ring is
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compromised during the conjugation of folic acid to MPNPs, the uptake efficiency would not be
significantly affected. Also, the conjugation might have occurred through the secondary amine of
p-aminobenzoate moity of folic acid. The uptake measurements in OVCAR3 cell line (vide infra)
showed that the uptake efficiency was indeed not compromised.
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Figure 5.1 A) FTIR spectra of FNPs (blue line) compared with MEH-PPV NPs (black line) and
MPNPs (red line). The three particular amide bands at 1620 cm-1- (amide I) for C=O stretch,
1580 cm-1 (amide II) for NH bend and 1312 cm-1 (amide III) in FNPs spectrum confirm the
formation of amide bond between amine of folic acid and carbonyl on MPNPs.
5.2.1.3 Zeta potential, UV-vis and fluorescence characterization
The zeta potential measurements revealed that the MPNPs have a negative zeta potential of -50.8
± 6.21 mV on them. The high negative charge on MPNPs might be due to the COOH groups
protruding out on the surface of MPNPs. This also confirms the assumption that the hydrophilic
parts of PS-PEG-COOH extends out on the surface of MPNPs. The FNPs also have a zeta
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potential of -48.9 ± 8.36 mV due to few conjugated folic acid molecules and the unreacted
COOH groups on the surface of FNPs (Table 5.1).
The optical properties of the MPNPs and FNPs were measured by UV-vis and fluorescence
spectroscopy (Figure 5.2A and B). The UV-vis spectra (Figure 5.2A) of the MPNPs (black line)
and FNPs before centrifugal filtration (red line) have max 497 nm while the max of FNPs after
centrifugal filtration (blue line) is blue shifted by 5 nm and has max at 492 nm. The blue shift in
the max might be attributed to compacting of the FNPs and collapse of polymer chains within the
FNPs when residual THF is extracted from the FNPs during the centrifugal filtration. The
collapse of the polymer chains inside the FNPs leads to severe kinking and bending of
conjugated backbone of polymers which results in reduced conjugation length leading to the blue
shift in absorption spectra [127, 241-243].
The fluorescence spectra (Figure 5.2B) of MEH-PPV have max at 589 nm, even though the
fluorescent intensity of the FNPs after filtration is drastically reduced to 40 %. This effect again
can be attributed to the removal of THF during centrifugal filtration. When THF is removed the
FNPs may become compacted, which can result in lowered quantum efficiency of fluorescence
due to self-quenching [244].
The presence of folic acid in FNPs suspension was confirmed by acquiring emission of folic acid
by exciting the FNPs at 300 nm (Figure 5.2C). The fluorescence spectrum of folic acid in FNPs
before filtration (red line) has max at 402 nm. After filtration the fluorescence intensity of folic
acid in FNPs (blue line) decreases as the unreacted folic acid is removed from the solution,
although the max remains unaltered.
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Figure 5.2 A) UV-vis spectra of NPs suspended in water. The absorption maxima for MPNPs
and FNPs before filtration are 497 nm. After filtration the absorption maximum shifts to 491 nm.
NP fluorescence spectra were collected for excitation at B) MEH-PPV absorption and C) folic
acid absorption. The max of emission spectra in B) for the three different NPs is 589 nm,
although the intensity of fluorescence is reduced to approximately 40 % after filtration. In C) the
fluorescence of folic acid has max at 402 nm. After filtration the observed intensity of folic acid
fluorescence is reduced due to removal of unreacted folic acid from FNP solution.

It has been previously been reported that MEH-PPV NPs fabricated by the reprecipitation
method have a diameter of about 35 nm in diameter [127]. When MPNPs were fabricated from a
mixture of 2:1 molar ratio of PS-PEG-COOH and MEH-PPV by the reprecipitation method, the
size was measured to be 45.12 ± 4.60 nm by DLS (Table 5.1). After folic acid conjugation the
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size of FNPs before filtration decreased slightly to 39.81 ± 5.12 nm as compared to MPNPs.
After filtration the size of FNPs increased to 68.80 ± 7.30 nm, which is attributed to aggregation
of a few FNPs.
Table 5.1 shows the size of NPs determined by DLS and the zeta potential on their surfaces. For
the unfiltered FNPs zeta potential data could not be obtained due to the free folic acid and excess
NHS and EDC present in solution.
MPNPs

FNPs(unfiltered)

FNPs(filtered)

DLS (nm)

45.12±4.60

39.81±5.12

68.80±7.30

Zeta
Potential
(mV)

-50.8 ± 6.21

-

-48.9 ± 8.36

5.2.1.4 Atomic force microscopy

MEH-PPV NPs- 27.3±6.7 nm

MPNPs- 35.1±5.2 nm

100 nm

100 nm

FNPs- 93.7±9.3 nm

200 nm

Figure 5.3 AFM images of MEH-PPV NPs, MPNPs and FNPs showing the size of the
nanoparticles
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The AFM data collected on MEH-PPV NPs, MPNPs and FNPs showed the sizes for these
nanoparticles as shown in Figure 5.3

5.2.2 Uptake of NPs in cell lines:
As the zeta potential on the surfaces of FNPs is -48.9±8.36 mV, it was expected that due to such
a high negative charge there would be no or limited non-specific uptake of FNPs in any of the
cell lines [166, 168, 174, 245]. Due to the presence of folic acid on FNPs, it was speculated that
regardless of the high negative charge on the surfaces of FNPs, a receptor mediated uptake of
FNPs would occur in cell lines which overexpress folate receptors (FRs) on their cell
membranes. Figure 5.4 shows the qualitative uptake of FNPs in OVCAR3, A549, MIA PaCa-2,
and TE 71 cell lines by epiluminescence imaging. As it is well known that over 90% of ovarian
cancer cells overexpress FRs [176, 246-249], and the expression of FRs on ovarian carcinoma is
very homogenous [250], OVACR3 cell line was selected as the FR positive (FR+) cell line to
observe the specific or receptor mediated uptake of FNPs. The expression of FRs in A549 is
marginal at best, if not absent [249, 251-259], while in MIA PaCa-2 cell line there are receptors
other than FRs (FR-), like thrombin receptors [260] or EGFR [261]. Thus these two cancer cell
lines were chosen as negative controls. TE 71 cell line was chosen as a control normal cell line
which has marginal to no FRs. It was observed that when all the four cell lines were incubated
with 2 x 10-4 mg/ml dose of FNPs, the uptake of FNPs was highest in OVCAR3 due to high
amount of FRs expressed in this cell line, while in A549 the uptake of FNPs was limited as it has
few to no FRs . MIA PaCa-2 and TE 71 have no detectable fluorescence suggesting no uptake of
FNPs in these cell lines. To rule out the possibility of non-specific uptake in OVCAR3 or in
A549, all the cell lines were incubated with equal dose of MPNPs which are not conjugated with
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folic acid (Figure 5.4). It was observed that there was no detectable fluorescence from MPNPs in
any of the four cell lines suggesting that there was no non-specific uptake of MPNPs. This
observation infers that for receptor mediated uptake of NPs, presence of FRs on cell membranes
and presence of folic acid on NPs surface was necessary.

MPNPs

FNPs

TE 71

MIA PaCa-2

A549

OVCAR3

Control (No NPs)

Figure 5.4 Uptake of FNPs in OVCAR3, A549, MIAPaCa2 and TE 71 cell lines. The
fluorescence images represent FNPs fluorescence (green) and DAPI fluorescence (blue). The
corresponding phase contrast images are also shown. The left column shows the control images,
the middle column shows images for cells treated with MPNPs and the right column shows
images for cells treated with FNPs.

To determine the selectivity of FNP uptake, flow cytometry was performed on the cell lines after
incubating them with a 2 x 10-4 mg/ml dose of FNPs. Figure 5.5 shows the flow cytometry
results. TE 71, MIA PaCa-2 and A549 data show that 0% cell population has uptaken FNPs,
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while for the OVCAR3 cell line 85% of the cell population has uptaken FNPs. Although
epiluminescence imaging shows small amounts of FNPs in A549 cells, flow cytometry was
unable to detect this fluorescence. In addition, PDT did not induce cell mortality in this case
(vide infra). The selectivity of the FNPs towards OVCAR3, which is the folate overexpressing
cell line, is easily explained by the conjugation of the FNPs with folic acid, while the limited
uptake by A549 is attributed to the few FRs available on the cell surface. In addition, the lack of
uptake by the other cell lines can be attributed to the hydrophobicity and the high negative zeta
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Figure 5.5 Uptake of FNPs quantified by flow cytometry for A) TE 71, B) MIA PaCa-2, C)
A549, and D) OVCAR3. Red line- normalized percent population of control cells, Green linenormalized percent population of cells incubated with FNPs. E) Bar graph indicating the
percentage of the cell population that has uptaken FNPs compared to the control (no FNPs). F)
Bar graph indicating the average fluorescence intensity of FNPs detected for the different cell
lines.
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5.2.3 Intrinsic cytotoxicity of FNPs:
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Figure 5.6 Intrinsic cytotoxicity of FNPs quantified by MTS viability assay for A) TE 71, B)
MIA PaCa-2, C) A549, and D) OVCAR3 cell lines incubated with different doses of FNPs and
kept in dark. MTS assays were run up to 96 hours after incubation with FNPs.
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The cytotoxicity of the FNPs in dark (intrinsic cytotoxicity) was studied by quantifying the
proliferation of the cell lines in presence of FNPs by MTS cell viability assay. Data are shown in
Figure 5.6 for TE 71, MIA PaCa-2, A549 and OVCAR3 cell lines. For each cell line the % cell
viability at each FNPs dose is normalized to the control dose. Cell viability was observed to be
about 100% at each dose of FNPs up to 96 hours. No cell mortality is observed for the TE 71 and
MIA PaCa-2 cell lines, which at first glance appears trivial due to the lack of FNP uptake.
However, the presence of the FNPs in the cell culture media also did not result in cell mortality.
For A549 limited FNP uptake was observed, while for OVCAR3 abundant FNP uptake occurred
(Figure 5.4). Again, in neither case cell mortality is observed. The FNPs clearly do not affect the
normal functioning of cells, and cells in the presence of FNPs proliferate normally.

5.2.4 Generation of oxidative stress in cells after PDT:
It is well known that when conducting polymers absorb light, it can intersystem cross and form
triplet excited states. In case of MEH-PPV the probability of intersystem crossing and forming
triplet excited states is 1.25% [220]. These triplet states can dissipate to the ground state by
energy transfer to triplet ground state of molecular oxygen to form the highly reactive singlet
oxygen (type I photooxidation) [75, 76, 81, 82]. In other instances, charge transfer can occur to
molecular oxygen to form superoxide or to other substrates such as solvent molecules and
biomolecules (lipids, DNA, nucleic acids etc.) to form radicals (type II photooxidation) [75, 76,
81, 82]. The reactive superoxide radicals then form hydrogen peroxide by grabbing an electron
which in presence of Fe (II) can form hydroxyl radicals [86, 130, 224, 225]. The hydroxyl
radicals lead to lipid peroxidation and cause damage to cell organelles [86]. Thus it was
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hypothesized that MEH-PPV, upon photoexcitation would effectively photosensitize the
formation of singlet oxygen or superoxide radicals, and that FNPs would not require a
photosensitizing dopant.
The generation of ROS in cells treated with FNPs and irradiated with light, i.e. PDT experiment,
was detected by CellRox Green reagent (CGR). CGR has weak to no fluorescence in its reduced
form. When CGR is oxidized by ROS in the cells, it displays bright green fluorescence. Figure
5.7D shows epiluminescence images of OVCAR3, A549, MIA PaCa2 and TE 71 cell lines
administered with 2 x 10-4 mg/ml FNPs and photoirradiated with 180 J/cm2 of light. After PDT
the cells were incubated for 2 hours before staining with CGR. The CGR fluoresces bright green
only in the OVCAR3 cell line as only OVCAR3 has uptaken FNPs and so ROS are generated
only in this cell line turning the CGR color bright green. Even though the A549 cell line has
shown small amounts of FNP uptake (Figure 5.4), that amount is not sufficient to produce ROS
detectable by CGR. MIA PaCa2 and TE 71 cell lines show no emission from CGR as there was
no uptake of FNPs, hence no ROS formation.
The fact that ROS formation in the cells is due to PDT and not intrinsic cytotoxicity of FNPs
such as previously observed for, for instance, quantum dots, which lead to elevated ROS even in
absence of light [210, 211], was confirmed by performing three negative controls stained with
CGR shown in Figure 5.7A-C (A) in absence of PDT (no FNPs, no light), B) in absence of FNPs
with 180 J/cm2 light dose, and C) in absence of light with 2 x 10-4 mg/ml FNPs dose). As no
emission from CGR was observed in Figure 5.7B, it can be concluded that there is no ROS
formation in absence of FNPs and that the light dosage alone did not form ROS. Thus, there is no
phototoxicity up to the 180 J/cm2 light dose. The phase contrast images show that the light has
no adverse effect on the morphology of the cells. Figure 5.7C show no CGR emission in any of
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the four cell lines when the cells are administered with FNPs but are not irradiated with light.
This confirms that ROS is not formed when the FNPs are not photoactivated. This is also a
confirmation test for the negative results of the intrinsic cytotoxicity by MTS assay when cells
are kept in dark (Figure 5.6). These negative controls show that FNPs if uptaken by the cells and
exposed to light are the source of ROS formation, hence the oxidative stress in the cells. Figure
5.7E is the positive control for formation of ROS in which all the cell lines are treated with
100µM H2O2.

OVCAR3

A549

MIA PaCa-2

TE 71

A

B

C

D

E

Figure 5.7 Detection of ROS generated after PDT in TE 71, MIA PaCa-2, A549 and OVCAR3
cell lines. A) negative control (no FNPs, no light), B) negative control with 180 J/cm2 (no FNPs)
indicates no photocytotoxicity is observed, C) negative control with 2 x 10-4 mg/ml FNPs (no
light) indicates no intrinsic cytotoxicity, D) 2 hours post-PDT , E) positive control with 100 µM
H2O2. Green color in (C) is fluorescence of FNPs. Green color in E and F is GreenRox dye
oxidized due to presence of ROS
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5.2.5 Quantitative measurements on cell viability after PDT:
The quantitative effect of PDT on the studied cell lines was measured by MTS cell viability
assays. Figure 5.8 shows the % cell viability after PDT. For each cell line the viabilities at the
three different FNPs doses (0.4 x 10-4 mg/ml, 2 x 10-4 mg/ml and 3.6 x 10-4 mg/ml) is compared
with the viability at the control FNPs dose (0 mg/ml). MTS assay was performed immediately
after PDT (0 hours) and 4 hours post-PDT to evaluate further progression after PDT (Figure 5.8).
It was shown previously that with the use of composite MEH-PPV/PCBM NPs for PDT, 4 hours
is a sufficient time to cause nearly 100% cell mortality [262]. The measurements revealed that
the viability of TE 71, MIA PaCa-2 and A549 cell lines is almost 100%. In OVCAR3 cell line,
the viability decreases with increase in FNPs dose. It is a well-accepted fact that 90% of ovarian
cancer cells overexpress FRs [176, 246-249], and the expression of FRs on ovarian carcinoma is
very homogenous [250]. Therefore, OVCAR3 cell line is considered as the FR+ cancer cell line.
Due to this there is receptor mediated uptake of the folic acid conjugated nanoparticles
preferentially in ovarian cancer cells [263, 264]. In A549 the expression of FRs is marginal
although not completely absent [176, 230, 265]. In MIA PaCa2 there is no FR overexpression
[260] [261] and so this is considered as the FR- cancer cell line. The TE 71 cell line has very less
to no FR expression and is the normal control cell line. Due to high overexpression of FR in
OVCAR3 the uptake of FNPs is abundant through receptor mediated endocytosis. As the FNPs
dose increases the amount of FNPs uptaken by the OVCAR3 cells increases. At the same time
the population of cells that uptake FNPs also increases. This increase in amount of FNPs in many
cells leads to formation of more ROS in the large number of cells, which reflects in low percent
cell viability. In MIA PaCa2 due to absence of FR expression, no FNPs uptake occurred and so
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the viability is almost 100%. In A549 due to less FR expression there is small uptake of FNPs
(Figure 5.4).
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Figure 5.8 MTS cell viability assay to quantify result from PDT for TE 71, MIA PaCa-2, A549
and OVCAR3 cell lines incubated with different doses of FNPs and irradiated with 3 doses of
light. The post-PDT incubation time is 0 and 4 hours.
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But the amount of FNPs is not sufficient for formation of oxidative stress in A549 cell line. Thus
the viability is approximately 100%. The TE 71 which also has less to no overexpression of FRs
on their plasma membranes, there is no uptake of FNPs and cell viability is 100%. Also, as the
light dose increases (60 J/cm2, 120 J/cm2 and 180 J/cm2) the cell viability in OVCAR3 cell line
decreases implying a larger amount of ROS formation with higher dose of light.

5.2.6 Quantification of PDT results by flow cytometry:
The pathway through which cell death occurs depends on 1) the photosensitizer and cell line
combination, 2) the PDT dosage and 3) the subcellular or subtissular localization of the
photosensitizer. Luo et al. showed that when photosensitizer chloroaluminum phthalocyanine
dispersed throughout the cytoplasm 90% of murine leukemia P388 cells underwent apoptosis at
low light dosage [266]. At higher dosage of light more membrane photodamage was observed,
which was found to inhibit apoptosis. Jori et al. have shown that PDT with zinc phthalocyanine
(ZnPc) photosensitizer in MS-2 fibrosarcoma induced random necrotic and apoptotic cell deaths
due to different subcellular and/or subtissular distribution of the photosensitizer [267]. Here, PI
and annexin V FITC staining was completed after PDT with 4 hours of post-PDT incubation to
evaluate cell death efficiency and pathways by flow cytometry. Flow cytometry data are shown
in Figure 5.9. The annexin V FITC fluorescence intensity is plotted on the x-axis and the PI
fluorescence is plotted on the y-axis. The red dots correspond with the control samples while the
black dots correspond with samples treated with PDT. The lower left quadrant in the dot plots
show cells which are viable. The lower right quadrants indicate cells which are positive for
annexin V-FITC, but negative for PI indicating apoptotic cells.
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Figure 5.9 Flow cytometry to quantify cell mortality after PDT. Dot plots are for A) TE 71, B)
MIA PaCa-2, C) A549 and D) OVCAR3 cell lines stained with FITC annexin V and PI. The red
dots are the cells from control and the black dots are the cells from PDT experiment. The four
quadrants in each plot are labeled for live (lower left), apoptotic (lower right), necrotic (upper
left) and dual stained cells (upper right) along with percentages in each quadrant. The data are
plotted as bar graphs for clarity in E-H. E) Percent cell viability in each cell line after PDT, F)
Percent of necrotic cells in each cell line after PDT, G) Percent of apoptotic cells after PDT, and
H) Relation between % cell population with FNPs and % cell death after PDT in each cell line.
In each bar graph the percentages are compared with the corresponding control experiments.
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The upper left quadrants show the fraction of the cell population exhibiting only PI fluorescence,
indicating necrotic cells. The cell population in the upper right quadrant is dual stained by
annexin V-FITC and PI. Looking at the flow cytometry data for PDT (black dots) in OVCAR3
cell line (Figure 5.9D), almost 75% of the cells are dual stained, 14 % cells are stained by PI only
(necrotic) and 6 % cells are stained by annexin V-FITC (apoptotic)..
For the dual stained cells, it is difficult to distinguish the cell death pathway. Arguments can be
made that the cells have undergone either apoptotic death, or necrotic death, or a random
combination of necrotic and apoptotic death. The first possibility is that the cells have gone
through apoptotic death, which would give a positive signal for fluorescence of annexin V-FITC.
Since these are in-vitro experiments there is no mechanism of phagocytosis to destroy the
apoptotic cells, which allows the cells go into the apoptotic necrosis stage. At this stage the cells
become permeable to PI stain and as a result become dual stained. The second possibility is that
the cells have gone through necrosis, which would give a positive signal for fluorescence of PI.
After cell death non-specific binding of annexin V-FITC to the cells becomes possible so that the
cells get stained with annexin V-FITC as well and show up in the dual stained quadrant of the
flow cytometry data. The third possibility is that different cells might have undergone both
necrotic or apoptotic deaths randomly to form a mixed population of apoptotic and necrotic cells.
For clarity the flow cytometry data was also plotted as bar graphs as shown in Figure 5.9E-H. It
can be seen from Figure 5.9E that the percentage of live cells in all the cell lines but OVCAR3 is
almost same as the control (no PDT) and that there is no death because of PDT as these cell lines
have not uptaken FNPs. On the other hand, in OVCAR3 cell line the percent of live cells is only
5. These data are very consistent with the data obtained by MTS cell viability assay (Figure 5.8).
Thus flow cytometry and MTS cell viability both confirm the effect of PDT on the cell lines
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studied here. The MIA PaCa2 cell line was found to be very sensitive to handle during culture
and was the reason of showing approximately 85% live cells in both control and PDT
experiment. The OVCAR3 cell line has 14% necrotic cells (Figure 5.9F) while only 6.5%
apoptotic cells (Figure 5.9G). The percent of dead cells is shown in Figure 5.9H. OVCAR3 has
almost 75% of dead cells. The % cell death in OVCAR3 cell line can be directly related to the %
cell population which has uptaken FNPs (green bars in Figure 5.9H).The % cell population
which has uptaken FNPs is 84. When PDT is performed on these cells, the % cell death is 75 and
can be directly related to the formation of ROS which leads to death. Figure 5.10 shows the
representative image of OVCAR3 cell line showing apoptotic and necrotic cells stained with
annexin V FITC ad PI depicting random combination of apoptosis and necrosis in the sample
after PDT.

Apoptotic
cells

Necrotic
cells

Dual stained
cell

Figure 5.10 Representative image of OVCAR3 cell line stained with PI, annexin V FITC and
DAPI after PDT is given to the cells. the image shows apoptotic and necrotic cells.

116

5.3

Localization of FNPs using Endosome and lysosome dyes
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B Dye fluorescence

C FNPs fluorescence
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Figure 5.11 OVCAR3 cells administered with FNPs and stained with 1) Early endosome dye and
2) lysosome dye for localization of FNPs inside the cells.

FNPs were localized by using the early endosome and lysosome dyes. From the figure it can be
seen that the FNPs are neither in the lysosomes nor in the early endosomes. This observation
might be due to energy transfer occurring from dye to polymer bleaching the dye, hence making
it harder to co-localize the polymer nanoparticles and lysosomes or endosomes. More work
needs to be done to localize the FNPs in cells, which could throw light on the uptake pathway.

5.4

Conclusion

Blended MEH-PPV/PS-PEG-COOH nanoparticles conjugated with folic acid (FNPs) were
studied in-vitro for use in PDT as next generation photosensitizers with targeted delivery. The
FNPs were found to be selectively targeting cancer cell lines that overexpress folate receptors
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(FR) and exhibited no dark toxicity. In-vitro PDT experiments show near complete cell mortality
for the cancer cell line that abundantly overexpresses the targeted receptor (OVCAR3) while no
cell mortality is observed for non-targeted (TE71 normal control and MIA PaCa2) or marginally
receptor overexpressing cell lines (A549).

The high extinction coefficient, effective ROS

generation, high degree of uptake selectivity, absence of dark toxicity, inclusion of PEG which
may enhance circulation times for in-vivo applications, and observation of cell mortality only for
abundantly receptor overexpressing target cell line indicate the promising nature of this
photosensitizer system for targeted PDT.
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CHAPTER 6
6.1

CdS:Mn/ZnS QDOT BIOSENSING PROBE

Introduction

In order to develop an understanding of the mechanisms by which cells perform functions in
normal and diseased situations, it is necessary to have knowledge of the biological environments
and the processes that occur in the cells at the molecular level. Processes that need to be
understood at the molecular level involve signaling pathways, migration of ions, protein
activities, and biomolecular interactions [268, 269]. Drug discovery and delivery is governed by
these questions as well. Such knowledge can ultimately aid in the design of new drugs, to deliver
these drugs in right amount, and selectively at the diseased sites [270, 271]. Biosensors are an
attractive tool to detect, image and quantify processes at molecular level. In a biosensor an
analyte such as a biomolecule or an ion is detected by combining a biological component with a
physical or chemical detector. Various biosensors have been reported and are still under study
that can report on biomolecular events.
Small molecules have been employed in the task of sensing biomolecules [272, 273].
Biomolecules such as glutathione, cysteine and homocysteine have been successfully detected
in-vitro by using MeO BODIPY-Cl molecules [274]. Reaction with thiol groups in biomolecules
lead to fluorescence turn-on in BODIPY. DNA based biosensors have also been designed to
detect DNA hybridization, microRNA, and DNA damage. DNA biosensors are based on
different types of sensing mechanisms such as optical, electrochemical and piezoelectric
properties [275, 276]. Genetically encoded fluorescent biosensors have been developed to image
and study protein activity and to observe small molecule signals and bimolecular interactions.
These biosensors use light emitting proteins to quantify protein activity or ligand binding
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through 1) FRET (fluorescence resonance energy transfer) measurements between a donor
protein (cyan fluorescent protein) and an acceptor protein (yellow fluorescent protein) [277-279],
2) spectral shift when a ligand binds to a protein [280, 281], and 3) by translocating within the
cell to get information on membrane lipids and biomolecules involved in signaling [282].
Aptamer based colorimetric biosensors can detect a wide variety of molecules such as Hg2+,
dopamine vitamin B12 etc. [283-287]. Nanomaterials such as, chitosan-carbon nanotube system,
(FITC-dextran) and (Rh-ConA) system have been used to detect glucose electrochemically and
by FRET mechanism respectively [288-290]. CdSe/ZnS quantum dots (Qdots) and gold (Au)
nanoparticles in which the Qdot was coordinated with Au nanoparticles through β-secretase
(BACE1) substrate peptide- Ni-nitrilotriacetate (Ni-NTA) conjugation, was used in-vitro for
sensing the BACE1 enzyme by a quenching and restoration mechanism through distance
dependent fluorescence resonance energy transfer (FRET) [291]. Surface plasmon resonance
(SPR) biosensors have shown promise due spectral sensitivity of their localized surface plasmon
resonance (LSPR) to nanoenvironments [292-296].
While these biosensors have resulted in impactful discoveries in developing our understanding of
molecular biology events in living systems, there are instances where analytical and shuttling
capabilities are needed. A particularly urgent example is drug delivery, where information on the
timing, localization and quantification of drug delivery in the intracellular environment is
typically missing. Nanoparticle biosensors have the potential to provide an answer for such
questions. Quantum dots (Qdots) have a size similar to that of a protein, exhibit bright
fluorescence and are photostable. These characteristics make Qdots excellent candidates for
developing a biosensor, and as a result Qdots have received considerable attention as biosensing
platforms [72, 73, 291, 297-303] that could advance our understanding of biomolecular events in
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living systems. Quenching of Qdots has been exploited to develop biosensors for quantification
of analyte. Citrate-capped Mn-modified CdSe/CdS Qdots were developed to detect tinidazole in
tablets and injections. The fluorescence of the Qdots quenched with increasing concentration of
tinidazole.[303]. Similarly, fluorescence quenching of GSH capped CdTe/CdS Qdots by
sanguinarine in aqueous solution was investigated to quantify sanguinarine in synthetic samples
and fresh urine samples in healthy humans [301]. While fluorescence quenching schemes have
brought tremendous progress in biosensing, the sensitivity of biosensors can be significantly
elevated by observing fluorescence restoration of a quenched state. Qdot fluorescence restoration
from a quenched (OFF) state to a bright (ON) state is particularly useful due to the ease of
detecting fluorescence emission of Qdots. Positively charged porphyrine has been shown to
quench negatively charged thioglycolic acid capped CdTe quantum dots (CdTe-TGA Qdots) via
electron transfer. It was found that calf thymus DNA (ctDNA) restores the fluorescence via
electron transfer mechanism, allowing for its detection by CdTe-TGA Qdots. Fluorescence
restoration occurs when porphyrins are removed from the Qdot surface and bind to ctDNA
interfering the electron transfer process between porphyrins and Qdots [302]. The same scheme
was used for ruthenium anticancer drug instead of porphyrine [72]. Detection of metal ions in
water has been reported as well. The ligand 1,10-phenanthroline was used to turn off Qdot
fluorescence by photoinduced hole transfer. Blocking of the hole transfer by formation of a metal
ion-phenanthroline complex restores the Qdot fluorescence in a concentration dependent manner
[298].
In the past few years, dopamine has been studied as a ligand that can quench Qdot fluorescence
due to its redox properties, specifically the ability to adopt catechol and quinone forms. Medintz
et al. have used CdSe/ZnS Qdots conjugated with a peptide-dopamine moiety to investigate the
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pH dependency of Qdot fluorescence quenching. At low pH dopamine is in its hydroquinone
(catechol) form and is a poor electron acceptor, resulting in bright Qdot fluorescence. When the
pH was increased, oxidation of hydroquinone leads to the formation of quinone form of
dopamine, which is a good electron acceptor. Thus electron transfer from Qdots to quinone leads
to quenching of the Qdot fluorescence. This pH sensing probe was applied to measure the
intracellular pH. [73, 299]. The Nadeau group has applied a fluorescence restoration scheme to
track CdSe/ZnS Qdot-dopamine probes in-vitro based on the redox properties of dopamine as
quenching ligand [300]. Fluorescence restoration was achieved by photooxidation during optical
imaging. Banerjee et al. reported CdS:Mn/ZnS-dopamine conjugates and proposed to use it for
detecting intracellular GSH[297].
In this article the in-vitro properties of activatable (OFF/ON) dopamine-CS2 conjugated
CdS:Mn/ZnS Qdots were investigated to determine the potential for application as an intracellular optical biosensor. The uptake and fluorescence restoration of Qdots to ON state in
OVCAR3 and A549 cell lines was confirmed by confocal microscopy and single particle
spectroscopy. Our findings give a promising proof of concept for the probe design.
6.2

Results and discussion
6.2.1 MMCNP with NAC as the linker

6.2.1.1 Probe design
Multifunctional/multimodal composite activatable nanoprobe (MMCNP) for optical tracking of
intracellular release of therapeutic drugs was developed. In addition to optical based tracking, the
MMCNP is integrated with MR imaging modality and selective cancer targeting functionality.
Briefly, MMCNP consists of a super-paramagnetic iron oxide (SPIO; ~ 20 nm size) core and
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satellite CdS:Mn/ZnS quantum dot (Qdots; 3.5 nm size) shell (Scheme 6.1). Each Qdot is
attached to core SPIO by a single hetero-bifunctional cross-linker molecule, dihydrolipoic acid
(DHLA). Next, an N-Acetyl-L-Cysteine (NAC) modified STAT 3 inhibitor (NAC-STAT3; a
therapeutic model drug), a NAC modified folate (NAC-FA; a cancer targeting agent) and a NAC
modified ethylenediamine (NAC-EDA, an amine modified ligand) were separately synthesized.
The Qdot surface was then decorated with NAC-STAT3, NAC-FA and finally with NAC-EDA.
The surface amine groups were reacted with N-hydroxysuccinimide (NHS) ester derivative of
methyl-poly-ethylene glycol (MPEG-NHS ester; a biocompatible highly-hydrophilic dispersing
agent) to improve overall dispersibility of the MMCNPs.

Scheme 6.1 Schematic representation of MMCNP in OFF state and ON state. Qdots are attached
to iron IONP. STAT3, folic acid and PEG are attached to these Qdots. When MMCNP reacts
with GSH the sulfur bonds between Qdots and IONP and between Qdots and drug are broken,
thus restoring fluorescence of Qdots.
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As expected, significant quenching of luminescence was observed once SPIO-Qdots are
conjugated to NAC-STAT3. Further quenching was observed upon treatment with NAC-FA. It
was noted that NAC itself did not quench Qdot luminescence, thus justifying the role of STAT 3
and FA as quenchers. The MMCNP is thus essentially in fluorescently quenched (“OFF”) state.
The luminescence of MMCNPs could be restored (“ON” state) upon treatment with an
appropriate agent that could effectively cleave disulfide bonds. Glutathione (GSH)[304], a
tripeptide biomolecule found in all animal cells at relatively high cytosolic concentration (~
5mM, reduced form), is a powerful electron donor. It effectively reduces disulfide bonds of
cytoplasmic proteins to cysteines and gets converted to glutathione disulfide, its oxidized form.
The design of MMCNPs is such that once it is exposed to intracellular glutathione environment,
it would be disintegrated by GSH. This forms the basis of intracellular tracking of STAT3
release as shown in Scheme 6.1.

6.2.1.2 Fluorescence restoration in solution with GSH
Fluorescence of MMCNPs is restored (“ON” state) in solution in about 30 minutes upon
interaction with GSH (λexc = 375 nm and λem = 588 nm) and about 5 fold increase in fluorescence
intensity is observed at 10 mM GSH concentration (Figure 6.1A). A systematic time-dependent
fluorescence restoration study was also conducted. Results showed that 2mM concentration of
GSH is sufficient to restore fluorescence completely in about an hour (Figure 6.1B).
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Figure 6.1 Fluorescence restoration of MMCNPs. A) restoration with 10 mM GSH with time, B)
graph showing 2 mM GSH is sufficient for complete restoration.

6.2.1.3 Fluorescence restoration at particle level wiith intracellular GSH

A

B

C

Figure 6.2 A) Bright field, B) Corresponding epi-luminescence laser microscopy images of
MDA-MB-231 cells incubated with MMCNPs for 5 h C) Normalized ensemble fluorescence
emission spectra acquired by sample scanning laser confocal microscopy under 375 nm laser
excitation.
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Confocal based imaging and spectroscopic studies were conducted for MMCNPs (drop casted
and air-dried) on a microscope slide. Fluorescence image and ensemble fluorescence emission
spectra of MMCNPs (“OFF” state, background signal) were recorded before and after the
addition of GSH solution (2 mM) (Figure 6.2C). It was observed that fluorescence brightness
exponentially increased. This is due to the restoration of fluorescence (“ON” state) from
MMCNPs, a direct evidence of release of quenchers. Fluorescence spectrum was significantly
broadened. Such broadening of emission spectrum is likely due to GSH induced aggregation of
Qdots. MDA-MB-231 cells after 5 hours incubation with folated MMCNPs showed similar
broadening of luminescence spectrum and aggregation of Qdots, thus confirming the formation
of GSH coated Qdots in cytosolic environment. Interestingly, majority of aggregated Qdots were
found near the cell membrane Figure 6.2B. It is expected that zwitterionic interaction among
GSH coated Qdots will not only reduce the surface area (increase in particle size) but also
significantly reduce surface polarity, thus increasing hydrophobicity. Such hydrophobic Qdots
aggregates will thus have tendency to accumulate close to cell membrane with reduced polar
environment.
6.2.2 Qdot-dopamine probe with CS2 linker
6.2.2.1 Probe design
The goal of the work reported here is to design an activatable (OFF/ON) dopamine-CS2
conjugated CdS:Mn/ZnS Qdot biosensor and evaluate the in-vitro properties to determine the
potential for application as an intracellular optical biosensor. The probe in this study consists of
Mn doped CdS/ZnS core/shell (CdS:Mn/ZnS) quantum dots modified by CS2-dopamine
conjugates on its surface (Scheme 6.2).
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A. DOP-NH2 + CS2

Triethylamine
Methanol

DOP-NH-CS2

B. DOP-NH-CS2 +
(OFF Probe)

+ GSH

S-GSH

(ON Probe)

+ DOP-NH-CS2
GSH --

-- CdS:Mn/ZnS Qdots, DOP-NH2 -Dopamine

Glutathione

Scheme 6.2 Illustration of the process to synthesize the OFF probe and subsequent fluorescence
restoration (ON probe). A) The dopamine-CS2 conjugate is prepared, and B) is attached to bare
Qdots to form the OFF probe. Addition of GSH to the OFF probe restores the fluorescence of
Qdots as GSH displaces the dopamine-CS2 conjugate.

During the fabrication of the OFF probe, in the first step the primary amine of dopamine forms a
stable carbodithioate product with CS2. The disulfide moiety on this product then couples with
the ZnS shell of the CdS:Mn/ZnS Qdots as shown in Scheme 6.2. The CS2 molecule achieves the
necessity of zero length covalent coupling of dopamine to the Qdots, facilitating electron transfer
processes between Qdots and dopamine in the probe that are at the basis of the OFF/ON sensing
mechanism. Dopamine is a well-known redox-active neurotransmitter that reversibly switches
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between a reduced state (catechol) and an oxidized state (benzoquinone), and quenches the Qdot
fluorescence by acting as electron donating or accepting moiety, resulting in the OFF state.
Glutathione (GSH), which is present in the intracellular environment, can displace the dopamine
ligand from the Qdot surface, thereby restoring fluorescence to the ON state (Scheme 6.2).

6.2.2.2 Probe characterization
6.2.2.2.1 FTIR
The FTIR spectrum of bare Qdots in Figure 6.3A and C has no distinct peaks except the broad
OH band at 3300 cm-1 due to the Zn(OH)2 formed on the Qdot crystal surface during the
crystallization process of ZnS semiconductor. The second important peak at 1589 cm -1 due the
C-S band confirms the presence of 19% AOT determined by thermogravimetric analysis (data
not shown).
When the dopamine-CS2 conjugate attaches to Qdots, the bare Qdot spectrum changes
significantly suggesting the Qdots are coated with dopamine-CS2 (Figure 6.3A and C OFF
probe), whereas the dopamine aromaticity seems to be lost due to the charge transfer processes
occurring between Qdots and the dopamine aromatic ring. Peaks that reflect aromaticity of
dopamine are not present in the data for the OFF probe (Figure 6.3B and D). The aromatic C=C
stretches at 1616 cm-1, 1600 cm-1, 1499 cm-1and 1472 cm-1 present in pure dopamine cannot be
seen in the OFF probe. Also, the out-of-plane aromatic C-H bend at 814 cm-1 has disappeared for
the OFF probe. The aromatic C-O stretch at 1284 cm-1 in dopamine now appears to be smaller in
the OFF spectrum while the 1260 cm-1 peak has disappeared completely. The aromatic C-H
stretches at 3070 cm-1 and 3039 cm-1, which can be seen embedded in the broad OH band in pure
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dopamine are not observed in OFF probe FTIR spectrum. The 3338 cm-1 peak for the N-H
stretch of the primary amine in dopamine now shifts to 3377 indicating a secondary amine is
present in the OFF probe.
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Figure 6.3 A) FTIR spectra of OFF probe, ON probe, and bare Qdot samples. B) FTIR spectra of
dopamine and GSH. C) and D) are the FTIR data from A) and B), respectively, expanded in the
absorption ranging from 2000 to 650 cm-1.

This secondary amine is due to the bond formation between -NH2 of dopamine and CS2. New
peaks also appear in the data collected for the OFF probe. Strong C=S stretches can be seen at
1589 cm-1, 1133 cm-1 and at 1042 cm-1. The medium bands at 1213 cm-1 and 1167 cm-1 are due to
the C-N stretch and appear for pure dopamine as well as for the OFF probe. The peaks at 1146,
1113 and 1080 cm-1 for dopamine belong to the C-N stretches and are buried under the strong CS
stretch at 1133 cm-1 observed for the OFF probe. The peak at 878 cm-1 due to N-H wagging
persists for both dopamine and the OFF probe.
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When GSH is added to the OFF probe, it displaces the dopamine-CS2 conjugate from the Qdot
surface. The FTIR spectrum of the ON probe shows very similar features to bare Qdots and GSH
(Figure 6.3B and D). No peaks related to dopamine are observed, which suggest that the
dopamine is removed from the surface of the Qdots. The only difference between the FTIR data
of pure GSH and GSH located on the Qdot surface is the S-H stretching band at 2522 cm-1
present for pure GSH. When GSH displaces dopamine, the hydrogen from S-H is replaced by the
Qdot surface and the 2522 cm-1 band disappears for the ON probe. The C-S stretches can be seen
at 1589 cm-1 for the ON probe. The presence of GSH on the Qdot surface is also confirmed by
the observation of the amide I, II and III at 1519, 1506 and 1395 cm-1 respectively for ON probe.

6.2.2.2.2 HRTEM
HRTEM characterization of OFF and ON probes, shown in Figure 6.4A and B, reveals the size
of a single Qdot crystal to be approximately 5 nm with lattice planes for CdS 101 and ZnS 110
(insets top left) [305]. HRTEM showed no changes in Qdot crystal structure of ON and OFF
probes. SAED data confirm the presence of the CdS core and ZnS shell with lattice spacings of
3.19 Å and 1.95 Å, respectively. EDX data confirm the presence of the Qdot in both samples
with no change in the elemental composition of the probe.
DLS measurements reveal large cluster sizes for the ON and OFF probes. The OFF probe cluster
size ranges from 75nm to 1µm, while after GSH treatment (ON probe) a size range of 230nm to
1µm is found. The OFF probe tends to aggregate in aqueous suspension due to the presence of
hydrophobic dopamine on the Qdot surface. After GSH addition, similar observations were
made. It is possible that the clusters formed by the OFF probe persist for the ON probe
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A

CdS (101)
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CdS (101)

ZnS (110)

ZnS (110)

Figure 6.4 High Resolution Transmission Electron Microscopy of (A) OFF probe and (B) ON
probe together with Selective Area Electron Diffraction (insets bottom right). Lattice spacing
remains consistent for both samples. Inner spacing and outer spacing are 3.14 Å and 1.95Å,
respectively. Diffraction patterns do not significantly change. The top left inset shows that
lattice planes can be seen for Qdot crystals of both samples (corresponding to yellow circles in
panels A and B).

6.2.2.3 Optical characterization
6.2.2.3.1 Uv-vis and Fluorescence solution spectroscopy
Optical characterization was completed on the OFF and ON probe, as well as bare Qdots and
bare Qdots treated with GSH as controls. The bare CdS:Mn/ZnS Qdots show broad structureless
absorption from the UV range to 500 nm (Figure 6.5A). The addition of GSH to bare Qdots
increases the absorption in the UV range only. Functionalizing the bare Qdot with dopamine
results in both a characteristic dopamine peak at 278nm, as well as increased absorption in the
UV range for the OFF probe compared to bare Qdots. When GSH is added to the OFF probe, the
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278nm dopamine peak becomes slightly suppressed, suggesting that the physical interaction
between the Qdot core and dopamine-CS2 was interrupted.
The fluorescence spectrum of bare Qdots depicted in Figure 6.5B (black line) shows the
characteristic 589 nm peak representative of the 4T1-6A1 transition of the Mn2+ dopants in Qdots
[306, 307]. Excitations in the CdS [306] decay nonradiatively to the Mn2+ unoccupied 3D states
via energy transfer, from where the d-d transition (4T1-6A1) leads to the orange fluorescence
[306, 307]. This emission peak remains unchanged even after dopamine is covalently conjugated
to the ZnS shell of the Qdots. However, the fluorescence intensity of Qdots is quenched by 90%
(red line) as compared to the bare Qdots. Dopamine present in reduced (catechol) or oxidized
(quinone) form can quench the Qdots by electron transfer processes between dopamine and
Qdots. In reduced form of dopamine the electron transfer occurs from dopamine catechol ring to
Qdots quenching the Qdots fluorescence [299, 300, 308] while in oxidized form of dopamine the
electron transfer occurs from Qdots to dopamine quinone ring [299, 300, 308]. When GSH is
added to this OFF Probe, immediate fluorescence restoration up to 50% is observed (blue line)
without any shift in peak emission wavelength, which remains at 589 nm. It is expected that the
disulfide bond of dopamine-CS2 conjugate is displaced by the sulfur of GSH restoring the
fluorescence of Qdots [297]. The fluorescence of bare Qdots was decreased by 10% when GSH
was added to it, suggesting that GSH has minimal quenching effect on Qdots. Surface exchange
of Qdots between GSH and covalently linked CS2-dopamine is a reversible process as both
molecules are capable of bonding with the Qdots through sulfide bonds. This also explains the
reason for not getting 100% fluorescence restoration.
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Figure 6.5 A) Absorption spectra showing bare Qdots, bare Qdots treated with GSH, the OFF
probe, which exhibits a peak at 278nm peak consistent with dopamine absorption and the ON
probe, which shows decreased absorption at the 278 nm peak. B) Fluorescence spectra were
recorded at 375nm excitation. All Qdot samples show the characteristic peak emission from the
Mn2+ dopant. Fluorescence restoration was observed after interaction of the OFF probe with
GSH.

Figure 6.6 shows data from a time-lapse study that tracks restoration of Qdot fluorescence for 30
minutes while GSH interacts with the probe. The restoration occurs within 15 seconds after
addition of GSH to the OFF probe. Qdot fluorescence intensity keeps increasing rapidly up to 5
minutes and after which it keeps increasing steadily by small increments upto 15 minutes and
then plateaus after 15 minutes.
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Figure 6.6 Time lapse restoration curve showing the fluorescence restoration of Qdots occurs
within 15 seconds after addition of GSH to the OFF probe. The data point at 0 min is the
fluorescence intensity of OFF probe.

6.2.2.3.2 Single particle spectroscopy
For detailed studies on the optical properties of the OFF probe and to evaluate the effect of GSH
on the OFF probe, single particle (aggregate) spectroscopy was performed.
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Figure 6.7 Single particle spectroscopy on bare Qdots, OFF probes, and ON probes (after
restoration of OFF probes by extracellular GSH). A) Ensemble spectra for new batch of probes
with catechol form of dopamine. B) Ensemble spectra for old batch of probes with quinone form
of dopamine. Each panel shows single particle ensemble spectra for bare Qdots (blue line), OFF
probe (black line) and ON probe (red line). C) A model is shown detailing possible charge
transfer pathways that result in OFF state probes. Pathways considered are from the catechol
ring of dopamine to the Qdot core of the probe (Pathways A1, A2, A3, and A4) and from the
Qdot core of the probe to the quinone form of dopamine (Pathways B1 and B2).The pathways
A1 and B1 shown in yellow are the most probable electron transfer pathways.
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For this the bare Qdots, the OFF probe and the ON probe (after addition of GSH to OFF probe)
samples were drop cast on glass substrates and dried in vacuum. Two different batches, a new
batch not exposed to oxygen and an old batch oxidized in air, were studied. Single particle
fluorescence data for the two batches of probes are shown in Figure 6.7A and B, respectively. In
both graphs, the ON and OFF probe single particle ensemble spectra are compared with the bare
Qdot spectra. For the new batch, the ensemble spectrum of the OFF probe shows quenched
fluorescence, with a decrease in fluorescence intensity by 90%. The ensemble spectrum of the
ON probe shows 60% fluorescence restoration after GSH addition. For the aged oxidized batch
the OFF probe spectrum shows only 30% quenching, while the brightness of the ON state is near
90% compared of the bare Qdots intensity. The prominent peak at 500 nm observed in the OFF
probe spectrum of the oxidized samples, which is absent in the data of pristine samples,
corresponds with the emission of oxidized dopamine [73, 300, 308]. The possibility of assigning
this peak to Qdot emission was discarded as CdS and ZnS emit at 525 nm and 550 nm [309,
310]. The absence of this peak in the ON spectrum in Figure 6.7B indicates removal of dopamine
after addition of GSH to the OFF probe. For both samples the peak emission of bare Qdots is red
shifted from 589 nm in solution (Figure 6.5B) to 610 nm. This red shift can be attributed to
drying and aggregation of Qdots as the samples were drop casted and dried before imaging. For
both the oxidized and pristine samples a shoulder can be seen at 650 nm for the OFF and ON
probes as seen from the normalized data shown in Figure 6.8. This emission is typically
indicative of defects on the Qdot core [310]. However, the pristine Qdot does not show a
noticeable shoulder while the oxidized bare Qdots again exhibit the shoulder at 650 nm. In
addition, the data in Figure 6.7B show that the intensity of this shoulder increases from bare
Qdots to OFF probe to ON probe. These observations indicate that ligand attachment introduces
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defects on the Qdot surface, besides the defect formation induced by oxidation. It is probable that
electrons become trapped in these defects, which could affect the process of electron transfer
from Qdots to the quinone form of dopamine. This may explain the lowered magnitude of
quenching for old batches of probe as can be seen in Figure 6.7B. Alternatively, the quinone
form of dopamine may not be an efficient quencher.
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Figure 6.8 Normalized fluorescence spectra showing the 650 nm shoulder in ON and OFF probes
in new batch, while in old batch the 650 nm shoulder can be seen increasing from bare Qdots to
OFF probe to ON probe.

The quenching of Qdot fluorescence is attributed to electron transfer processes between Qdot
and dopamine. Whether the transfer is from or to the Qdots depends on the oxidation state of the
dopamine attached to it. Electron transfer occurs from dopamine to Qdots when dopamine is in
its reduced form (catechol), while electron transfer occurs from Qdots to dopamine when
dopamine is in the oxidized form (quinone). A model for these electron transfer mechanisms in
CdS:Mn/ZnS-dopamine probe is represented in Figure 6.7C, and mirrors the model proposed for
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CdSe/ZnS-dopamine conjugates [299]. In the case of CdS:Mn/ZnS-dopamine the electron
transfer from the reduced catechol ring of dopamine could occur to the 4T1 level of Mn2+ (A3),
but this process may be less likely since excitons migrate from the Qdot core to the Mn 2+ d states
via energy transfer within a few picoseconds to block that pathway [306, 311, 312]. The process
of electron transfer from catechol to the valence band of CdS (A2) might be blocked for the same
reason, although the rate of this process is unknown. The electron transfer process from catechol
to conduction band of CdS can happen (A4), but Qdot may not result in quenching unless the
electron quickly moves on to the 4T1 level of Mn2+. The most plausible electron transfer that
results in fluorescence quenching is from the catechol excited state to the 6A1 state of Mn2+ (A1).
The electron can recombine with holes in the Mn2+ valence band, subsequently quenching the
emission. The long-lived orange transition 4T1 to 6A1 state has a lifetime on the order of 1 to 2
ms, which makes this process more probable to occur. When the quinone form of dopamine is
involved, electron transfer may occur from the 4T1 level of Mn2+ (B1) or from the CdS
conduction band (B2) to the unoccupied molecular orbital of the quinone ring of dopamine. The
B2 process may be less likely since exciton migration from Qdots to Mn2+ d states occurs on the
picosecond scale. Conversely, as the life time of 4T1 state is 1-2 ms, the B1 process seems more
likely to happen.

6.2.2.4 In-vitro evaluation
6.2.2.4.1 Epiluminescence and confocal microscopy
The intracellular behavior of the probe was studied with A549 human lung cancer, OVCAR3
human ovarian cancer and TE 71 normal mouse epithelial cell lines. Figure 6.9 shows the
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epiluminescence images of these three cell lines incubated with the probe for 24 hours. The red
spots in the images indicate the probe inside the cells. No probe fluorescence was detected for
the TE 71 control cell line; while there is detectable fluorescence of the probe in the A549 and
OVCAR3 cell lines. Overall, very small amounts of uptake can be seen in cancer cell lines. This
limited uptake by cancer cell lines can be attributed to the aggregation of the probe in aqueous
media together with the absence of dopamine receptors on the cell surfaces.

OVCAR3

TE 71

With Probe

Without Probe

A549

Figure 6.9 Overlaid epiluminescence and phase contrast images for A549, OVCAR3 and TE 71
cell lines incubated with and without probe. The bright red (false color) spots localize the ON
probe, indicating that the probe is inside the cells, which is confirmed by confocal microscopy.
Qdots appear to be in the ON state for cancer cell lines, while no fluorescence was detected in
the TE 71 cell line, suggesting no detectable uptake occurred for the latter. Faint emission can be
detected in regions on the substrate away from cells, suggesting these probes remained in the
OFF state.
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In case of the cells which express dopamine receptors, the reduced form of dopamine is bound to
the dopamine receptors on cells by hydrogen bonds between hydroxyl groups on catechol form
of dopamine and serins on the receptor [313, 314]. However, none of the cell lines studied herein
have dopamine receptor overexpression. This rules out the possibility of dopamine (catechol)
related specific uptake of probes. Still, the oxidized form of dopamine (quinone) is bound by the
sulphhydryl of cysteines present in several proteins located on the cell membrane [313, 315].
Thus it is possible that oxidized dopamine ligands on the Qdot probe facilitate cysteine mediated
uptake. Another reason of having very small amount of uptake is that the probes have limited
dispersibility in aqueous environment. This may lead to precipitation of probes from DMEM
media, leading to limited availability to cells. The OFF probe can be seen outside the cells with
very low fluorescence as shown in Figure 6.9. The bright red spots on the cells can be considered
as ON state probe as the intracellular GSH detaches the dopamine from Qdots restoring its
fluorescence. While the details on the uptake mechanism of probes by the different cell lines are
yet to be understood, it is reasonable to claim that particles eventually end up in the cytosolic
environment. This statement is supported by the fact that probe restoration requires GSH, which
is present in the cytosol.
To confirm that the probe is uptaken by the cells and is not stuck on the cell wall confocal
fluorescence microscopy was performed on OVCAR3 cell line which was administered with
0.05 mg/ml of probe. The slices were acquired at 0.3 µm for a height of 6.3 µm. The image in
the Figure 6.10 shows the z stack of the composite of DIC and fluorescence images. The z stack
confirms that the probe is inside the cell.
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Figure 6.10 3D confocal imaging of an OVCAR3 cell confirms that the Qdot probe entered the
cell, corroborated by the bright fluorescence (ON state, false color).

6.2.2.4.2 Intracellular single particle spectroscopy
The intracellular single particle spectroscopy was performed on the same samples of A549 and
OVCAR3 cells for which epiluminescence imaging was completed. Figure 6.11A and C show
the confocal fluorescence raster scan images of OVCAR3 and A549 cells. Figure 6.11B and D
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show the ensemble spectra acquired for these images. The fluorescence images are the overlay of
the autofluorescence of cells (shown in grey false color) and fluorescence of probe (shown in red
false color). Each ensemble spectrum is an average of 50 spectra acquired on multiple cell
images.
Figure 6.11B and D shows that OVCAR3 cells have autofluorescence max at 482 nm while
A549 cells autofluoresces with peak emission at 473 nm. The OFF probes have low fluorescence
intensity as expected due to the quenching of Qdot fluorescence by the attached dopamine
ligands. These spectra were acquired from the red spots outside the cells. The max for these
spectra are at 587 nm (OVCAR3) and 593 nm (A549) with a blue shoulder around 475 nm which
is attributed to autofluorescence of the cells. The presence of an autofluorescence peak in the
OFF state probe indicates that the probe is stuck on the cell membrane and is not exposed to the
cytosolic environment. The ensemble spectrum of the ON probe in OVCAR3 (Figure 6.11B) has
max at 623 nm, which is 36 nm red shifted as compared to the OFF probe. The ensemble
spectrum of the ON probe in A549 (Figure 6.11D) has max at 610 nm, which is 17 nm red
shifted as compared to OFF probe. The fluorescence intensity is almost doubled in the ON state
spectra for both the cell lines. This is due to the detachment of dopamine from the OFF probe
upon interaction with intracellular GSH, indicating that the probe has entered the cell and has
been exposed to the cytosolic environment. Broadening and red shifts observed for the ON
spectra in both the cell lines can be attributed to the aggregation of Qdots inside cells and also to
the increase in defects or sulfur vacancies in the Qdots. In addition, when comparing the data for
the ON probe observed for the A549 and OVCAR 3 cell lines, the intensity of the shoulder at
650 nm is noticeably higher for the OVCAR3 case. The mechanism behind this observation is
not fully understood at this time and will require further study.
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Figure 6.11 Single particle spectroscopy on Qdot probes that entered OVCAR3 and A549 cells,
i.e. ON state. Representative images of A) OVCAR3 and C) A549 cells constructed by
overlaying the autofluorescence (grey, false color) acquired by using a 480/30 band pass filter
and probe fluorescence (red, false color) collected by 585/20 band pass filter. Image size is 50
µm. Ensemble fluorescence spectra (the average of 50 spectra collected from multiple cells) of
the ON probe in the intracellular environment were collected for the B) OVCAR3 and D) A549
cell lines. The ON probe in OVCAR3 cells has max at 623 nm (black line) which is 36 nm red
shifted as compared to the OFF probe in OVCAR3 cells (red line), which has its max at 587 nm.
The autofluorescence of OVCAR3 cells (blue line) is at max 482 nm. For A549 the
autofluorescence max is at 473 nm. In A549 cells the ON probe has max at 610 nm which is 17
nm red shifted compared to max 593 nm of the OFF probe.
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Potentially, this observation suggests that the Qdots internalized by OVCAR3 have either
developed more defects or are more strongly aggregated, possibly in larger clusters.

6.3

Conclusion

The development of a CdS:Mn/ZnS biosensor that can use the redox properties of dopamine to
detect the intracellular drug delivery events was achieved. Conjugation of dopamine ligand to
CdS:Mn/ZnS Qdots through carbon disulfide (zero length coupling) efficiently quenched the
Qdot fluorescence through electron transfer processes between Qdots and dopamine. The
electron transfer occurs from or to Qdots depending on attachment of oxidized form of dopamine
(quinone) or reduced form dopamine (catechol) respectively. The fluorescence was restored up
to 60% by extracellular GSH in which the sulfide bonds from dopamine-CS2 conjugation were
replaced by sulfide bonds from GSH. The intracellular GSH Qdot restored the Qdot fluorescence
by releasing dopamine moiety inside the cells, thus giving a promising proof of concept for the
probe design. .
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